REVVITY, INC., 10-K filed on 2/24/2026
Annual Report
v3.25.4
Cover Page - USD ($)
 12 Months Ended
Dec. 28, 2025
Feb. 20, 2026
Dec. 29, 2024
Jun. 28, 2024
Jun. 30, 2023
Entity Listings [Line Items]          
Document Annual Report true        
Entity Well-known Seasoned Issuer Yes        
Entity Voluntary Filers No        
Entity Current Reporting Status Yes        
Entity Interactive Data Current Yes        
Entity Public Float       $ 11,298,522,046  
ICFR Auditor Attestation Flag true        
Entity Shell Company false        
Document Financial Statement Error Correction [Flag] false        
Sale of Stock, Price Per Share         $ 97.82
Common stock, par value $ 1   $ 1    
Document Type 10-K        
Document Period End Date Dec. 28, 2025        
Document Transition Report false        
Entity File Number 001-5075        
Entity Registrant Name REVVITY, INC.        
Entity Incorporation, State or Country Code MA        
Entity Tax Identification Number 04-2052042        
Entity Address, Address Line One 77 4th Avenue        
Entity Address, City or Town Waltham,        
Entity Address, State or Province MA        
Entity Address, Postal Zip Code 02451        
City Area Code 781        
Local Phone Number 663-6900        
Entity Current Reporting Status Yes        
Entity Interactive Data Current Yes        
Entity Filer Category Large Accelerated Filer        
Entity Small Business false        
Entity Emerging Growth Company false        
Entity Common Stock, Shares Outstanding   111,799,374      
Entity Central Index Key 0000031791        
Document Fiscal Year Focus 2025        
Document Fiscal Period Focus FY        
Amendment Flag false        
Current Fiscal Year End Date --12-28        
RVTY [Member]          
Entity Listings [Line Items]          
Trading Symbol RVTY        
Trading Symbol RVTY        
RVTY 26 [Member]          
Entity Listings [Line Items]          
Trading Symbol RVTY 26        
Trading Symbol RVTY 26        
Common stock, $1 par value per share [Member]          
Entity Listings [Line Items]          
Title of 12(b) Security Common Stock, $1 par value per share        
Title of 12(b) Security Common Stock, $1 par value per share        
1.875% Notes due 2026 [Member]          
Entity Listings [Line Items]          
Title of 12(b) Security 1.875% Notes due 2026        
Title of 12(b) Security 1.875% Notes due 2026        
NEW YORK STOCK EXCHANGE, INC. [Member]          
Entity Listings [Line Items]          
Security Exchange Name NYSE        
Security Exchange Name NYSE        
v3.25.4
Audit Information
 12 Months Ended
Dec. 28, 2025
Audit Information [Abstract]  
Auditor Name DELOITTE & TOUCHE LLP
Auditor Location Boston, Massachusetts
Auditor Firm ID 34
v3.25.4
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 28, 2025
Feb. 20, 2026
Jun. 28, 2024
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 28, 2025    
Document Transition Report false    
Entity File Number 001-5075    
Entity Registrant Name REVVITY, INC.    
Entity Central Index Key 0000031791    
Current Fiscal Year End Date --12-28    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Amendment Flag false    
Entity Incorporation, State or Country Code MA    
Entity Tax Identification Number 04-2052042    
Entity Address, Address Line One 77 4th Avenue    
Entity Address, City or Town Waltham,    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02451    
City Area Code 781    
Local Phone Number 663-6900    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 11,298,522,046
Entity Common Stock, Shares Outstanding   111,799,374  
Documents Incorporated by Reference
Portions of Revvity, Inc.’s Definitive Proxy Statement for its Annual Meeting of Shareholders to be held on April 28, 2026 are incorporated by reference into Part III of this Form 10-K.
    
Common stock, $1 par value per share [Member]      
Entity Information [Line Items]      
Title of 12(b) Security Common Stock, $1 par value per share    
1.875% Notes due 2026 [Member]      
Entity Information [Line Items]      
Title of 12(b) Security 1.875% Notes due 2026    
NEW YORK STOCK EXCHANGE, INC. [Member]      
Entity Information [Line Items]      
Security Exchange Name NYSE    
RVTY [Member]      
Entity Information [Line Items]      
Trading Symbol RVTY    
RVTY 26 [Member]      
Entity Information [Line Items]      
Trading Symbol RVTY 26    
v3.25.4
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Revenue      
Segment revenue $ 2,856,051 $ 2,755,026 $ 2,750,571
Segment selling, general and administrative expenses 991,890 994,074 1,022,551
Segment research and development expenses 215,840 196,844 216,578
Operating income from continuing operations 356,635 346,741 300,562
Interest and other expense, net 88,358 30,615 117,586
Income from continuing operations before income taxes 268,277 316,126 182,976
Provision for income taxes 28,394 33,055 3,473
Income from continuing operations 239,883 283,071 179,503
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 1,318 (12,686) 513,591
Net income $ 241,201 $ 270,385 $ 693,094
Basic earnings per share:      
Income from continuing operations $ 2.06 $ 2.31 $ 1.44
Income from discontinued operations and dispositions 0.01 (0.10) 4.12
Net income 2.07 2.21 5.56
Diluted earnings per share:      
Income from continuing operations 2.06 2.30 1.44
Income from discontinued operations and dispositions 0.01 (0.10) 4.11
Net income $ 2.07 $ 2.20 $ 5.55
Product [Member]      
Revenue      
Segment revenue $ 2,389,984 $ 2,338,211 $ 2,415,893
Cost of Product and Service Sold 1,117,132 1,041,749 1,077,744
Service [Member]      
Revenue      
Segment revenue 466,067 416,815 334,678
Cost of Product and Service Sold $ 174,554 $ 175,618 $ 133,136
v3.25.4
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Net income $ 241,201 $ 270,385 $ 693,094
Other comprehensive income (loss)      
Foreign currency translation adjustments, net of income taxes, recognized in other comprehensive income 173,876 (119,260) 80,172
Foreign currency translation adjustments, net of income taxes, reclassified to earnings 0 0 90,814
Net foreign currency translation adjustments, net of income taxes 173,876 (119,260) 170,986
Unrealized gains (losses) on securities, net of tax 94 (153) (181)
Other comprehensive income (loss) 173,970 (119,413) 170,805
Comprehensive income $ 415,171 $ 150,972 $ 863,899
v3.25.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Current assets:    
Cash and cash equivalents $ 919,860 $ 1,163,396
Accounts receivable, net 744,671 632,400
Inventories 379,497 367,587
Other current assets 195,719 186,225
Total current assets 2,239,747 2,349,608
Property, plant and equipment, net 479,249 482,217
Operating Lease, Right-of-Use Asset 165,439 167,716
Intangible assets, net 2,347,003 2,640,921
Beginning balance 6,613,493 6,463,619
Other assets, net 323,480 288,397
Total assets 12,168,411 12,392,478
Current liabilities:    
Current portion of long-term debt 588,828 242
Accounts payable 185,464 167,463
Accrued expenses and other current liabilities 556,954 485,395
Total current liabilities 1,331,246 653,100
Long-term debt 2,631,236 3,150,476
Long-term liabilities 807,461 770,523
Operating Lease, Liability, Noncurrent 148,108 151,505
Total liabilities 4,918,051 4,725,604
Commitments and contingencies (see Note 16)
Stockholders' equity:    
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding 0 0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 112,281,000 and 120,646,000 shares at December 28, 2025 and December 29, 2024, respectively 112,281 120,646
Capital in excess of par value 1,305,900 2,097,110
Retained earnings 6,054,314 5,845,223
Accumulated other comprehensive loss (222,135) (396,105)
Total stockholders' equity 7,250,360 7,666,874
Total liabilities and stockholders' equity $ 12,168,411 $ 12,392,478
v3.25.4
Consolidated Balance Sheet Parenthetical - $ / shares
Dec. 28, 2025
Dec. 29, 2024
Balance Sheet Parenthetical [Abstract]    
Preferred stock, par value $ 1 $ 1
Preferred stock, authorized 1,000,000 1,000,000
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value $ 1 $ 1
Common stock, authorized 300,000,000 300,000,000
Common stock, issued 112,281,000 120,646,000
Common stock, outstanding 112,281,000 120,646,000
v3.25.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock Amount [Member]
Common Stock Amount [Member]
Net Income [Member]
Common Stock Amount [Member]
Other comprehensive loss [Member]
Common Stock Amount [Member]
Dividends [Member]
Common Stock Amount [Member]
Exercise of employee stock options and related income tax benefits [Member]
Common Stock Amount [Member]
Purchases of common stock [Member]
Common Stock Amount [Member]
Issuance of common stock for employee stock purchase plans [Member]
Common Stock Amount [Member]
Issuance of common stock for long-term incentive program [Member]
Common Stock Amount [Member]
Stock compensation [Member]
Capital In Excess of Par Value [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Common stock, outstanding   (126,300,000)                      
Beginning Balance at Jan. 01, 2023 $ 7,382,876 $ 126,300                 $ 2,753,055 $ 4,951,018 $ (447,497)
Net income 693,094                     693,094  
Other comprehensive income (loss) 170,805                        
Dividends 34,900                     34,900 0
Exercise of employee stock options and related income tax benefits 4,344 58                 4,286    
Issuance of common stock for employee benefit plans 3,132 29                 3,103    
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations 392,302 3,267                 389,035    
Issuance of common stock for long-term incentive program 35,192 306                 34,886    
Stock compensation 10,498 0                 10,498 0 0
Ending Balance at Dec. 31, 2023 7,872,739 $ 123,426                 2,416,793 5,609,212 (276,692)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 79,991                        
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax 170,805                       170,805
Common stock, outstanding   (123,426,000) 0 0 0 (58,000) (3,267,000) (29,000) (306,000) 0      
Net income 270,385                     270,385  
Other comprehensive income (loss) (119,413)                        
Dividends 34,374                     34,374  
Exercise of employee stock options and related income tax benefits 7,701 $ 117                 7,584    
Issuance of common stock for employee benefit plans 1,428 14                 1,414    
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations 369,368 3,146                 366,222    
Issuance of common stock for long-term incentive program 28,066 235                 27,831    
Stock compensation 9,710 0                 9,710 0 0
Ending Balance at Dec. 29, 2024 7,666,874 $ 120,646                 2,097,110 5,845,223 (396,105)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (119,413)                        
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax $ (119,413)                       (119,413)
Common stock, outstanding (120,646,000) (120,646,000) 0 0 0 (117,000) (3,146,000) (14,000) (235,000) 0      
Net income $ 241,201                     241,201  
Other comprehensive income (loss) 173,970                        
Dividends 32,110                     32,110  
Exercise of employee stock options and related income tax benefits 2,926 $ 36                 2,890    
Issuance of common stock for employee benefit plans 2,661 27                 2,634    
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations 828,056 8,546                 819,510    
Issuance of common stock for long-term incentive program 13,713 118                 13,595    
Stock compensation 9,181 0                 9,181 0 0
Ending Balance at Dec. 28, 2025 7,250,360 $ 112,281                 $ 1,305,900 $ 6,054,314 (222,135)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 173,970                        
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax $ 173,970                       $ 173,970
Common stock, outstanding (112,281,000) (112,281,000) 0 0 0 (36,000) (8,546,000) (27,000) (118,000) 0      
v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 921,030 $ 1,164,452 $ 914,373 $ 470,746
Operating activities:        
Net income 241,201 270,385 693,094  
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest (1,318) 12,686 (513,591)  
Income from continuing operations 239,883 283,071 179,503  
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:        
Restructuring Charges and Changes in Estimates 55,932 17,454 26,601  
Depreciation and amortization 405,340 427,849 431,769  
Stock-based compensation 22,847 37,809 41,410  
Pension and other post-retirement expense 3,639 9,381 23,089  
Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) (1,400) (1,869) 4,168  
Deferred taxes (61,483) (102,232) (123,664)  
Contingencies and Non-Cash Tax Matters (86) (8,073) 26,183  
Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts 4,552 6,073 7,349  
Asset Impairment Charges 4,784 22,814 0  
Change in fair value of investments 11,456 (7,958) 33,921  
Gain (Loss) on Extinguishment of Debt 0 0 (3,685)  
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax 273 (1,059) 24,089  
Changes in assets and liabilities which (used) provided cash, excluding effects from companies purchased and divested:        
Accounts receivable, net (101,023) (15,969) (8,997)  
Inventories, net 14,782 45,086 (14,109)  
Accounts payable 7,345 (26,025) (76,426)  
Accrued expenses and other (17,885) (21,397) (291,814)  
Net cash provided by operating activities of continuing operations 588,956 664,955 279,387  
Net cash used in operating activities of discontinued operations (6,023) (36,656) (188,115)  
Net cash provided by operating activities 582,933 628,299 91,272  
Investing activities:        
Capital expenditures (73,522) (86,648) (81,368)  
Purchases of investments and notes receivables (385) (6,587) (6,300)  
Payments to Acquire Marketable Securities 0 0 (1,221,609)  
Proceeds from Sale and Maturity of Marketable Securities 0 710,000 550,000  
Proceeds from Divestiture of Businesses 304 2,500 153  
Cash paid for acquisitions, net of cash acquired 0 0 (2,086)  
Net cash (used in) provided by investing activities of continuing operations (73,603) 619,265 (761,210)  
Net cash provided by investing activities of discontinued operations 56,250 156,897 2,074,734  
Net cash (used in) provided by investing activities (17,353) 776,162 1,313,524  
Financing activities:        
Payments of Senior Debt 0 (711,479) (523,808)  
Payments of debt financing and equity issuance costs (2,474) 0 (15)  
Proceeds from (Repayments of) Other Debt (521) (11,593) 6,323  
Payments for acquisition-related contingent consideration (3,838) (8,832) (10,117)  
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 2,925 7,701 4,344  
Purchases of common stock (820,815) (369,578) (388,882)  
Dividends paid (32,800) (34,454) (34,966)  
Net cash (used in) provided by financing activities (857,523) (1,128,235) (947,121)  
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 48,521 (26,147) (14,048)  
Net (decrease) increase in cash, cash equivalents and restricted cash (243,422) 250,079 443,627  
Cash and cash equivalents at beginning of year 1,163,396 913,163    
Restricted Cash, Current 6 1,056 1,210  
Restricted Cash, Noncurrent 1,164 0 0  
Cash and cash equivalents at end of year 919,860 1,163,396 913,163  
Supplemental disclosures of cash flow information        
Interest Paid, Excluding Capitalized Interest, Operating Activity 86,195 91,092 94,008  
Income taxes   154,900 359,800  
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]        
Consideration receivable from sale of Business $ 0 $ 0 $ 241,353  
v3.25.4
Interest and Other Expense (Income), Net
 12 Months Ended
Dec. 28, 2025
Other Income and Expenses [Abstract]  
Interest and Other Expense (Income), Net Interest and Other Expense, Net
Interest and other expense, net, consisted of the following for the fiscal years ended:
 
December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Interest income$(31,103)$(73,190)$(72,131)
Interest expense92,185 96,278 98,813 
Change in fair value of investments11,456 (7,958)33,921 
Other components of net periodic pension cost871 8,508 19,006 
Foreign exchange losses and other expense, net14,949 6,977 37,977 
Total interest and other expense, net$88,358 $30,615 $117,586 
v3.25.4
Interest and Other Expense (Income), Net
 12 Months Ended
Dec. 28, 2025
Other Income and Expenses [Abstract]  
Interest and Other Expense (Income), Net
Interest and other expense, net, consisted of the following for the fiscal years ended:
 
December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Interest income$(31,103)$(73,190)$(72,131)
Interest expense92,185 96,278 98,813 
Change in fair value of investments11,456 (7,958)33,921 
Other components of net periodic pension cost871 8,508 19,006 
Foreign exchange losses and other expense, net14,949 6,977 37,977 
Total interest and other expense, net$88,358 $30,615 $117,586 
v3.25.4
Interest and Other Expense (Income), Net - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Interest income $ (31,103) $ (73,190) $ (72,131)
Change in fair value of investments 11,456 (7,958) 33,921
Other components of net periodic pension cost (credit) 871 8,508 19,006
Foreign exchange losses and other expense (income), net 14,949 6,977 37,977
Total interest and other expense, net 88,358 30,615 117,586
Interest Expense, Nonoperating $ 92,185 $ 96,278 $ 98,813
v3.25.4
Nature of Operations and Accounting Policies
 12 Months Ended
Dec. 28, 2025
Accounting Policies [Abstract]  
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies
Nature of Operations:    Revvity, Inc. (the “Company”) is a leading provider of health sciences solutions, technologies, expertise and services that deliver complete workflow from discovery to development, and diagnosis to cure. The Company has two operating segments: Life Sciences and Diagnostics. The Company’s Life Sciences segment focuses on service and innovating for customers spanning the life sciences market. The Company’s Diagnostics segment is targeted towards meeting the needs of clinically-oriented customers, especially within the growing areas of reproductive health and emerging market diagnostics.
The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a
52/53-week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 28, 2025 (“fiscal year 2025”), December 29, 2024 (“fiscal year 2024”) and December 31, 2023 (“fiscal year 2023”) included 52 weeks. The fiscal year ending January 3, 2027 (“fiscal year 2025”) will include 53 weeks.
Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Revenue Recognition: The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The Company recognizes revenue in an amount that reflects the consideration the Company expects to receive in exchange for the promised products or services when a performance obligation is satisfied by transferring control of those products or services to customers.
Taxes that are collected by the Company from a customer and assessed by a governmental authority, that are both imposed on and concurrent with a specific revenue-producing transaction, are excluded from revenue.
The Company reports shipping and handling revenue in revenue, to the extent it is billed to customers, and the associated costs in cost of product revenue.
Inventories: Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements.
Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not.
The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. These reserves are based on a determination of whether a tax benefit taken by the Company in its tax filings is more likely than not to be sustained upon audit based on its technical merits. The tax benefit recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense.
The Company is subject to the Global Intangible Low Taxed Income (“GILTI”) tax in the U.S. The Company elected to treat taxes on future GILTI inclusions in U.S. taxable income as a current period expense when incurred.
The Company uses the portfolio approach for releasing income tax effects from accumulated other comprehensive income.
Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings - 10 to 40 years; leasehold improvements - estimated useful life or remaining term of lease, whichever is shorter; machinery and equipment - 3 to 10 years; and capitalized internal-use software - 3 to 10 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed. The Company capitalizes certain qualified costs incurred in connection with the development of internal-use software. The Company evaluates the costs incurred during the application development stage of internal use software to determine whether the costs meet the criteria for capitalization. Costs related to preliminary project activities and post implementation activities are expensed as incurred.
Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company’s fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds.
Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive income (“AOCI”), a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net.
Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses. Measurement period adjustments are made in the period in which the amounts are determined, and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.
Goodwill and Other Intangible Assets:  The Company’s intangible assets consist of (i) goodwill, which is not being amortized; and (ii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives.
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. The Company's annual goodwill impairment testing date is the later of November 1 or the first day of its eleventh fiscal month of each fiscal year. Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values.
Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model or the quoted price of the Company’s stock on the grant date. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The
determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock. The Company recognizes the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation.
 Marketable Securities and Investments:  Investments in debt securities that are classified as available for sale are recorded at fair value with unrealized gains and losses included in AOCI until realized. Investments in debt securities that are classified as held-to-maturity are recorded at amortized cost. Investments in equity securities are recorded at fair values with unrealized holding gains and losses included in earnings. Investments in equity securities without a readily determinable fair values are carried at cost minus impairment, if any. When an observable price change in orderly transactions for the identical or a similar investment of the same issuer has occurred, the Company elects to carry those equity investments at fair value as of the date that the observable transaction occurred.
Cash and Cash Equivalents: The Company considers all highly liquid, unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.
Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.
 Research and Development: Research and development costs are expensed as incurred.
Restructuring and Other Costs: Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period.
Comprehensive Income:  Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.
Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting.
For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive income (loss) and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements.
The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold.
Leases: Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets represent the Company’s right to use an
underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized based on the present value of the remaining lease payments over the lease term. When the Company’s lease did not provide an implicit rate, the Company used its incremental borrowing rate in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.
The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component.
The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statements of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred.
As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under Accounting Standards Codification 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with Accounting Standards Codification 842, Leases (“ASC 842”).
Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
In December 2025, the FASB issued Accounting Standards Update 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities (“ASU 2025-10”), which establishes authoritative guidance on the recognition, measurement, presentation, and disclosure of government grants. Under ASU 2025-10, government grants are recognized when it is probable that the entity will both comply with the conditions of the grant and the grant will be received. ASU 2025-10 provides specific accounting models for grants related to assets and grants related to income, including options to recognize government grants as deferred income or as a reduction of the asset’s cost basis. ASU 2025-10 also requires enhanced disclosures regarding the nature of government grants, significant terms and conditions, accounting policies applied, and amounts recognized in the financial statements. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-10 but does not expect the impact of such adoption to be material.
In December 2025, the FASB issued Accounting Standards Update 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (“ASU 2025-11”), which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. ASU 2025-11 provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-11.
In September 2025, the FASB issued Accounting Standards Update 2025-06, Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”). ASU 2025-06 amends certain aspects of the accounting for and disclosure of software costs. The amendments in this update are effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The guidance may be applied prospectively, retrospectively, or via a modified prospective transition method. The Company is in the process of determining the impact of this guidance on its financial statements and disclosures.
In November 2024, the FASB issued Accounting Standards Update 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”). ASU 2024-03 requires public entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items. Such disclosures are required on an annual and interim basis in a tabular presentation in the footnotes to the financial statements. In addition, ASU 2024-03 requires public
entities to disclose selling expenses on an annual and interim basis. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is in the process of determining the impact of this guidance on its financial statements and disclosures.
In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 will require public entities to disclose on an annual basis a tabular reconciliation using both percentages and amounts, broken out into specific categories with certain reconciling items at or above 5% of the statutory (i.e. expected) tax further broken out by nature and/or jurisdiction. ASU 2023-09 requires all entities to disclose on an annual basis the amount of income taxes paid (net of refunds received), disaggregated between federal (national), state/local and foreign, and amounts paid to an individual jurisdiction when 5% or more of the total income taxes paid. The Company adopted the guidance in fiscal year 2025 on a prospective basis and has included the additional disclosures related to income taxes in Note 6, Income Taxes.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]
Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
In December 2025, the FASB issued Accounting Standards Update 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities (“ASU 2025-10”), which establishes authoritative guidance on the recognition, measurement, presentation, and disclosure of government grants. Under ASU 2025-10, government grants are recognized when it is probable that the entity will both comply with the conditions of the grant and the grant will be received. ASU 2025-10 provides specific accounting models for grants related to assets and grants related to income, including options to recognize government grants as deferred income or as a reduction of the asset’s cost basis. ASU 2025-10 also requires enhanced disclosures regarding the nature of government grants, significant terms and conditions, accounting policies applied, and amounts recognized in the financial statements. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-10 but does not expect the impact of such adoption to be material.
In December 2025, the FASB issued Accounting Standards Update 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (“ASU 2025-11”), which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. ASU 2025-11 provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-11.
In September 2025, the FASB issued Accounting Standards Update 2025-06, Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”). ASU 2025-06 amends certain aspects of the accounting for and disclosure of software costs. The amendments in this update are effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The guidance may be applied prospectively, retrospectively, or via a modified prospective transition method. The Company is in the process of determining the impact of this guidance on its financial statements and disclosures.
In November 2024, the FASB issued Accounting Standards Update 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”). ASU 2024-03 requires public entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items. Such disclosures are required on an annual and interim basis in a tabular presentation in the footnotes to the financial statements. In addition, ASU 2024-03 requires public
entities to disclose selling expenses on an annual and interim basis. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is in the process of determining the impact of this guidance on its financial statements and disclosures.
In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 will require public entities to disclose on an annual basis a tabular reconciliation using both percentages and amounts, broken out into specific categories with certain reconciling items at or above 5% of the statutory (i.e. expected) tax further broken out by nature and/or jurisdiction. ASU 2023-09 requires all entities to disclose on an annual basis the amount of income taxes paid (net of refunds received), disaggregated between federal (national), state/local and foreign, and amounts paid to an individual jurisdiction when 5% or more of the total income taxes paid. The Company adopted the guidance in fiscal year 2025 on a prospective basis and has included the additional disclosures related to income taxes in Note 6, Income Taxes.
v3.25.4
Revenue from Contract with Customer
 12 Months Ended
Dec. 28, 2025
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block] Revenue
For arrangements with multiple performance obligations, the Company accounts for individual products and services separately if they are distinct - i.e., if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated to each performance obligation in an arrangement based on relative stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis.
The Company sells products and services predominantly through its direct sales force, and the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty).
In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year.
Nature of goods and services
The Life Sciences segment principally generates revenue from sales of instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services in the life sciences market. The Diagnostics segment principally generates revenue from sales of instruments, solutions, consumables, reagents, and services in the diagnostics market. The typical length of a contract for service is 12 to 36 months.
The revenue generated from the sale of instruments, reagents, and certain software is recognized at a point in time. The Company recognizes revenue in these arrangements at the point in time when control of the products has been transferred to customers, which is typically at delivery. Certain of the Company’s products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. When the Company places the instrument at the customer's site and sells the reagents to a customer, the instrument and reagents are accounted for together as one performance obligation. The Company does not charge a fee for the use of the instrument and retains ownership of the placed instrument. The Company recognizes revenue upon delivery of reagents, which is the point in time where the Company has performed its obligation to provide a screening solution to the customer. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days.
The revenue generated from the sale of licenses for software as a service, cloud services, subscriptions, and laboratory services and training is recognized over time. Software as a service, subscriptions and cloud services, are generally recognized ratably over the contract period. The Company sells its software subscriptions and cloud services with maintenance services and, in some cases, with consulting services. The Company recognizes revenue for the software commencing when the service is made available to the customer. For maintenance and consulting services, revenue is recognized over the period in which the services are provided. Revenue for laboratory services is recognized over the contract period or when the service is billable, based on an input method that is based on time and materials.
Product revenue is recognized at a point in time and service revenue is generally recognized over time.
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical market and major good and service lines.
Reportable Segments
For the fiscal year ended
December 28, 2025December 29, 2024December 31, 2023
Life
 Sciences		DiagnosticsTotalLife SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$750,857 $505,104 $1,255,961 $745,206 $477,881 $1,223,087 $759,782 $455,831 $1,215,613 
Europe343,507 481,471 824,978 315,173 427,441 742,614 344,713 402,310 747,023 
Asia336,740 438,372 775,112 338,222 451,103 789,325 353,697 434,238 787,935 
$1,431,104 $1,424,947 $2,856,051 $1,398,601 $1,356,425 $2,755,026 $1,458,192 $1,292,379 $2,750,571 
Major goods/service lines
Life Sciences Solutions$1,194,728 $— $1,194,728 $1,197,802 $— $1,197,802 $1,279,903 $— $1,279,903 
Software236,376 — 236,376 200,799 — 200,799 178,289 — 178,289 
Immunodiagnostics— 869,908 869,908 — 828,627 828,627 — 787,394 787,394 
Reproductive health— 555,039 555,039 — 527,798 527,798 — 504,985 504,985 
$1,431,104 $1,424,947 $2,856,051 $1,398,601 $1,356,425 $2,755,026 $1,458,192 $1,292,379 $2,750,571 

Major Customer Concentration
No single customer comprises more than 10% of net revenues in the years presented.
Contract Balances
Unbilled receivable and Contract assets: The timing of revenue recognition may differ from the timing of customer billing. When revenue is recognized prior to billing and the right to the amount due from customers is conditioned only on the passage of time, the Company records an unbilled receivable on its consolidated balance sheets. The unbilled receivables are classified as either current in “Accounts receivable, net” or as long-term in “Other assets, net” in the consolidated balance sheets. Unbilled receivables totaled $105.6 million and $80.6 million at December 28, 2025 and December 29, 2024, respectively, primarily related to software revenue. The Company has no material contract assets as of December 28, 2025 and December 29, 2024.
Deferred revenue and Customer deposits: Deferred revenue is recorded when revenue is recognized subsequent to customer invoicing. Deferred revenue is classified as either current in “Accrued expenses and other current liabilities” or as long-term in “Long-term liabilities” in the consolidated balance sheets based on the timing of when the Company expects to recognize revenue. Substantially all of the deferred revenue is expected to be recognized in revenue within 12 months of the balance sheet date, and has been classified within accrued expenses and other current liabilities. The deferred revenue balance is primarily related to our software as a service offerings, maintenance contracts and prepaid storage arrangements. Deferred revenue totaled $224.8 million and $212.8 million at December 28, 2025 and December 29, 2024, respectively. The Company also has customer deposits received in advance of the transfer of control totaling $19.3 million and $19.5 million at December 28, 2025 and December 29, 2024, respectively. The Company expects that these customer deposits will be recognized in revenue within 3 months of the balance sheet date.
Transaction price allocated to the remaining performance obligations
The Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.
v3.25.4
Discontinued Operations
 12 Months Ended
Dec. 28, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations Discontinued Operations
During fiscal year 2023, the Company completed the sale of certain assets and the equity interests constituting the Company’s Applied, Food and Enterprise Services businesses (the “Business”) for approximately $2.27 billion in cash proceeds before transaction costs. The Business was a component of the Company’s Discovery & Analytical Solutions segment, which is now referred to as the Life Sciences segment. The sale of the Business was reported as discontinued operations in the Company’s consolidated financial statements.
The Company was entitled to an additional $75.0 million in proceeds payable in installments to commence upon the Company’s ceasing the use of the PerkinElmer brand and related trademarks and transferring them to the buyer (the “Brand Fee”). During fiscal years 2025 and 2024, the Company received $56.2 million and $18.8 million, respectively, of the Brand Fee.
The following table summarizes the results of discontinued operations which are presented as income from discontinued operations in the Company’s consolidated statements of operations:
 December 28, 2025December 29, 2024December 31, 2023
 (In thousands)
Revenue$— $— $176,324 
Cost of revenue— — 125,219 
Selling, general and administrative expenses— — 78,613 
Research and development expenses— — 10,434 
Operating loss— — (37,942)
Other (loss) income:
(Loss) gain on sale(817)(25,448)811,472 
Other expense, net— — (49)
Total other (loss) income(817)(25,448)811,423 
(Loss) income from discontinued operations before income taxes(817)(25,448)773,481 
(Benefit from) provision for income tax(2,135)(12,762)259,890 
Income (loss) from discontinued operations$1,318 $(12,686)$513,591 
The capital expenditures from discontinued operations for the fiscal year 2023 were not material.
v3.25.4
Restructuring and Related Activities
 12 Months Ended
Dec. 28, 2025
Restructuring and Related Activities [Abstract]  
Restructuring and Other Costs Disclosure [Text Block] Restructuring and Other Costs
Restructuring and other costs in fiscal year 2025 primarily included charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities.
In fiscal year 2025, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the Company’s workforce.
Restructuring and other costs in fiscal years 2024 and 2023 primarily included charges for workforce reductions and facility consolidations, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. Severance actions associated with facility consolidations and cost reduction initiatives were not material to the Company’s overall workforce in both fiscal years.
Restructuring and other costs, included in the selling, general and administrative expenses in the consolidated statements of operations, by segment are as follows:
 
December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Life Sciences$15,552 $4,532 $6,203 
Diagnostics39,337 12,539 15,465 
Corporate1,043 383 4,933 
$55,932 $17,454 $26,601 
The following table summarizes the changes in the Company’s accrued restructuring balance for fiscal year 2025. The changes in accrued restructuring balance for fiscal years 2024 and 2023 were not material. Other amounts reported as restructuring and other costs during fiscal year 2025 in the accompanying statement of income have been summarized in the notes to the table. Remaining obligations related to these accounts are expected to be paid over the next 12 months and are included in the accrued expenses and other current liabilities in the consolidated balance sheets.
(In thousands)
Balance at December 29, 2024$3,836 
Net restructuring charges incurred in 2025 (a)
28,167 
Payments(14,210)
Balance at December 28, 2025$17,793 
(a) Excludes $27.8 million of charges, principally $20.8 million for asset impairment and $0.8 million of lease abandonment charges in the Diagnostics segment and $6.2 million of lease abandonment charges in the Life Sciences segment.
v3.25.4
Earnings Per Share
 12 Months Ended
Dec. 28, 2025
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended:

December 28,
2025		December 29,
2024		December 31,
2023
(In thousands)
Number of common shares—basic116,542 122,756 124,704 
Effect of dilutive securities:
Stock options15 57 108 
Restricted stock awards38 9 — 
Number of common shares—diluted116,595 122,822 124,812 
Number of potentially dilutive securities excluded from calculation due to antidilutive impact1,290 951 1,089 
Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive securities also include restricted stock awards with average unrecognized compensation cost in excess of the average fair market value of the common stock for the related period. Antidilutive options and restricted stock awards were excluded from the calculation of diluted net income per share and could become dilutive in the future.
v3.25.4
Accounts Receivable, Net
 12 Months Ended
Dec. 28, 2025
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]  
Accounts Receivable, Net Accounts Receivable, Net
Accounts receivable, net consisted of the following:
 
December 28,
2025		December 29,
2024
(In thousands)
Accounts receivable, net$744,671 $632,400 
Long-term accounts receivable, net, included in Other assets, net38,008 28,163 
Total accounts receivable, net$782,679 $660,563 
Reserves for credit losses consisted of the following:
Balance at Beginning of YearProvisionsCharges/
Write-offs
Other(1)
Balance at End
of Year
  (In thousands)
Year ended December 31, 2023$37,543 $9,067 $(3,559)$329 $43,380 
Year ended December 29, 202443,380 9,715 (4,487)(636)47,972 
Year ended December 28, 2025
47,972 2,476 (3,513)1,128 48,063 
(1) Other amounts primarily relate to the impact of foreign exchange movements.
v3.25.4
Inventories, Net
 12 Months Ended
Dec. 28, 2025
Inventory Disclosure [Abstract]  
Inventories, Net Inventories, Net
Inventories, net consisted of the following:
 
December 28,
2025		December 29,
2024
(In thousands)
Raw materials$173,033 $174,502 
Work in progress68,983 65,191 
Finished goods137,481 127,894 
Total inventories, net$379,497 $367,587 
v3.25.4
Property, Plant and Equipment, Net
 12 Months Ended
Dec. 28, 2025
Property, Plant and Equipment, Net [Abstract]  
Property, Plant and Equipment, Net Property, Plant and Equipment, Net
Property, plant and equipment consisted of the following:
December 28,
2025		December 29,
2024
(In thousands)
At cost:
Land$33,016 $29,521 
Building and leasehold improvements391,098 364,556 
Machinery and equipment534,711 486,614 
     Capitalized internal-use software134,309 101,193 
Total property, plant and equipment1,093,134 981,884 
Accumulated depreciation(613,885)(499,667)
Total property, plant and equipment, net$479,249 $482,217 
Depreciation expense on property, plant and equipment for the fiscal years 2025, 2024 and 2023 were $69.8 million, $68.5 million and $66.7 million, respectively. During fiscal year 2025, as part of the restructuring actions, the Company recognized an asset impairment amounting to $20.8 million related to certain property and equipment, which is included in Note 4, Restructuring and other costs, and in Selling, general and administrative expenses in the consolidated statements of operations. During fiscal year 2024, the Company recognized an asset impairment amounting to $22.8 million related to capitalized internal-use software in the Diagnostics segment, which is included in Selling, general and administrative expenses in the consolidated statements of operations.
v3.25.4
Marketable Securities and Investments
 12 Months Ended
Dec. 28, 2025
Marketable Securities [Abstract]  
Marketable Securities and Investments Marketable Securities and Investments
 Investments consisted of the following:
 
December 28,
2025		December 29,
2024
(In thousands)
Marketable securities - available for sale$27,956 $27,413 
Equity investments49,814 56,170 
Notes receivables and other investments12,366 12,337 
$90,136 $95,920 
Marketable securities - available for sale. Marketable securities, which are included in Other assets, net, are accounted for as available for sale and include equity and fixed-income securities. The net unrealized holding gain and loss on marketable securities, net of income taxes, reported as a component of other comprehensive income (loss) in the consolidated statements of stockholders’ equity, was not material. The proceeds from the sales of securities and the related gains and losses are not material for any period presented.
Equity investments. The Company has equity interests in privately-held entities over which the Company neither has significant influence nor control. Equity investments, which are included in Other assets, net, in the consolidated balance sheets, have no readily determinable fair values and are carried at cost less any impairment.
The amount of upward adjustments during the periods presented were not material. The cumulative amount of upward adjustments as of each of December 28, 2025 and December 29, 2024 was $31.3 million. The amount of asset impairment and downward adjustments during fiscal years 2025 and 2024 were $13.3 million and $2.1 million, respectively. The cumulative amount of impairments and downward adjustments as of December 28, 2025 and December 29, 2024 was $20.5 million and $7.1 million, respectively. The impairments were measured using fair value estimates developed using an income approach as well as consideration of comparable assets, which are level 3 measurements.
Notes receivables and other investments. Notes receivables and other investments, which are included in Other assets, net, in the consolidated balance sheets, are carried at cost less allowance for credit losses. The amortized cost of these investments are not materially different than the fair value. Notes receivables and other investments with a notional amount and carrying value of $0.4 million are convertible into equity securities or are due within one to five years if not converted. Notes receivables and other investments with a notional amount and carrying value of $12.0 million are convertible into equity securities or are due and payable upon an event of default (as defined in the applicable agreement). The credit losses, included in Interest and other expense, net, in the consolidated statements of operations, during fiscal years 2024 and 2023 were $1.8 million and $34.5 million, respectively.
v3.25.4
Goodwill and Intangible Assets, Net
 12 Months Ended
Dec. 28, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
The changes in the carrying amount of goodwill for fiscal years 2025 and 2024 are as follows:
Life SciencesDiagnosticsConsolidated
(In thousands)
Balance at December 31, 2023$4,587,938 $1,945,612 $6,533,550 
Foreign currency translation(46,471)(23,460)(69,931)
Balance at December 29, 20244,541,467 1,922,152 6,463,619 
Foreign currency translation105,495 44,379 149,874 
Other98,000 (98,000)— 
Balance at December 28, 2025
$4,744,962 $1,868,531 $6,613,493 

Amortizable intangible asset balances at December 28, 2025 and December 29, 2024 were as follows:
December 28,
2025		December 29,
2024
(In thousands)
Patents$27,592 $27,808 
Less: Accumulated amortization(26,524)(26,293)
Net patents1,068 1,515 
Trade names and trademarks150,103 142,588 
Less: Accumulated amortization(102,234)(87,824)
Net trade names and trademarks47,869 54,764 
Licenses27,561 27,164 
Less: Accumulated amortization(19,849)(17,855)
Net licenses7,712 9,309 
Core technology1,624,925 1,561,831 
Less: Accumulated amortization(921,325)(735,532)
Net core technology703,600 826,299 
Customer relationships2,870,384 2,807,909 
Less: Accumulated amortization(1,283,630)(1,058,875)
Net customer relationships1,586,754 1,749,034 
Net amortizable intangible assets$2,347,003 $2,640,921 
Total amortization expense related to amortizable intangible assets was $335.6 million in fiscal year 2025, $359.4 million in fiscal year 2024 and $365.1 million in fiscal year 2023. Estimated amortization expense related to amortizable intangible assets for each of the next five years is $332.2 million in fiscal year 2026, $304.7 million in fiscal year 2027, $278.7 million in fiscal year 2028, $249.3 million in fiscal year 2029, and $221.5 million in fiscal year 2030.
v3.25.4
Debt
 12 Months Ended
Dec. 28, 2025
Debt Disclosure [Abstract]  
Debt Debt
 The Company’s debt consisted of the following:
December 28, 2025
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(2,857)$(2,857)
1.900% Senior Unsecured Notes due in 2028 (“2028 Notes”)
500,000 (148)(1,791)498,061 
3.3% Senior Unsecured Notes due in 2029 (“2029 Notes”)850,000 (1,169)(3,235)845,596 
2.55% Senior Unsecured Notes due in March 2031 (“March 2031 Notes”)400,000 (75)(1,952)397,973 
2.250% Senior Unsecured Notes due in September 2031 (“September 2031 Notes”)
500,000 (919)(2,641)496,440 
3.625% Senior Unsecured Notes due in 2051 (“2051 Notes”)400,000 (3)(3,974)396,023 
Total Long-Term Debt2,650,000 (2,314)(16,450)2,631,236 
Current Portion of Long-Term Debt:
€500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”)
589,450 (343)(279)588,828 
Total Current Portion of Long-Term Debt589,450 (343)(279)588,828 
Total Debt$3,239,450 $(2,657)$(16,729)$3,220,064 
December 29, 2024
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(1,208)$(1,208)
2026 Notes521,700 (834)(780)520,086 
2028 Notes500,000 (200)(2,408)497,392 
2029 Notes850,000 (1,448)(4,010)844,542 
March 2031 Notes400,000 (88)(2,294)397,618 
September 2031 Notes500,000 (1,065)(3,059)495,876 
2051 Notes400,000 (4)(4,059)395,937 
Other Debt Facilities, non-current233 — — 233 
Total Long-Term Debt3,171,933 (3,639)(17,818)3,150,476 
Current Portion of Long-Term Debt:
Other Debt Facilities, current242 — — 242 
Total Current Portion of Long-Term Debt242 — — 242 
Total Debt$3,172,175 $(3,639)$(17,818)$3,150,718 
Senior Unsecured Revolving Credit Facility. The Company entered into a senior unsecured revolving credit facility in 2021 (the “2021 Senior Unsecured Revolving Credit Facility”) with a five-year term and a borrowing capacity of $1.5 billion available through August 24, 2026. On January 7, 2025, the 2021 Senior Unsecured Revolving Credit Facility was replaced with a new senior unsecured revolving credit facility with a five-year term and a borrowing capacity of $1.5 billion available through January 7, 2030. Borrowings will bear interest, payable quarterly or, if earlier, at the end of any interest period, at the Company’s option at either (a) the base rate (as described in the credit agreement), or (b) the Term Secured Overnight Financing Rate (“Term SOFR”) (as described in the credit agreement), in each case plus a percentage spread based on the credit rating of the Company’s debt. The base rate is the highest of (a) the Federal Funds Rate (as defined in the credit agreement) plus 0.50%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate”, and (c) Term SOFR plus 1.00%. The credit agreement for the new facility contains customary affirmative, negative and financial covenants and events of default. The financial covenants include a debt-to-capitalization ratio that remains applicable for so long as the Company’s debt is rated as investment grade. In the event that the Company’s debt is not rated as investment grade, the debt-to-capitalization ratio covenant is replaced with leverage ratio and interest coverage ratio covenants.
The following table summarizes the maturities of the Company’s indebtedness as of December 28, 2025: 
(In thousands)
2026$589,450 
2027— 
2028500,000 
2029850,000 
2030— 
2031 and thereafter1,300,000 
Total debt payments$3,239,450 
v3.25.4
Accrued Expenses and Other Current Liabilities
 12 Months Ended
Dec. 28, 2025
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Accrued Expenses and Other Current Liabilities Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following:
 
December 28,
2025		December 29,
2024
(In thousands)
Payroll and incentives$71,406 $74,984 
Employee benefits48,128 44,183 
Deferred revenue160,194 140,212 
Federal, non-U.S. and state income taxes80,565 74,403 
Operating lease liabilities
30,035 23,582 
Other accrued operating expenses166,626 128,031 
Total accrued expenses and other current liabilities$556,954 $485,395 
v3.25.4
Employee Benefit Plans
 12 Months Ended
Dec. 28, 2025
Retirement Benefits [Abstract]  
Employee Benefit Plans Employee Benefit Plans
 Savings Plan: The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Savings plan expense was $13.8 million in fiscal year 2025, $13.3 million in fiscal year 2024, and $15.0 million in fiscal year 2023.
Pension Plans: The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan is closed to new hires and plan benefits
have been frozen. The plans provide benefits that are based on an employee’s years of service and compensation near retirement.
In December 2024, the Company entered into an annuity purchase agreement to irrevocably transfer a portion of the U.S. pension benefit obligation to a third-party insurance company. The annuity purchase price was $94.1 million and was funded from U.S. pension plan assets. The resulting settlement of the U.S. pension plan was not material and is included in the actuarial gains and losses recognized during fiscal year 2024.
In January 2025, the Company executed a sale of its United Kingdom (“UK”) pension plan to a third party as part of a multi-year buy-out plan. Following satisfaction of all obligations in the buy-out agreement, excess plan assets of $2.7 million, net of taxes, reverted to the Company. The resulting settlement of the UK pension plan was not material and was included in the actuarial gains and losses recognized during fiscal year 2025.
As of December 28, 2025, all the principal non-U.S. pension plans are unfunded.
 Net periodic pension cost for U.S. and non-U.S. plans included the following components for fiscal years ended:
December 28,
2025		December 29,
2024		December 31,
2023
(In thousands)
Service and administrative costs$3,253 $5,017 $5,736 
Interest cost9,398 17,008 19,585 
Expected return on plan assets(4,003)(12,899)(14,600)
Actuarial (gains) losses(5,188)1,188 9,341 
Net periodic pension cost$3,460 $10,314 $20,062 
The Company recognizes actuarial gains and losses, unless an interim remeasurement is required, in the fourth quarter of the year in which the gains and losses occur. Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company’s control, including changes in interest rates, the performance of the financial markets and mortality assumptions. Actuarial gains and losses, including other components of periodic pension cost, are recognized in the line item “Interest and other expense, net” in the consolidated statements of operations.
The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 28, 2025 and December 29, 2024.
 December 28, 2025December 29, 2024
Non-U.S.U.S.Non-U.S.U.S.
(In thousands)
Actuarial present value of benefit obligations:
Accumulated benefit obligations$132,279 $91,185 $212,120 $90,293 
Change in benefit obligations:
Projected benefit obligations at beginning of year$212,120 $90,293 $227,579 $208,505 
Service and administrative costs1,811 1,425 3,442 1,575 
Interest cost4,476 4,922 7,966 9,042 
Benefits paid and plan expenses(8,045)(8,717)(14,770)(20,986)
Plan settlements(89,351)— — (96,270)
Actuarial (gains) losses(4,065)3,262 (2,950)(11,573)
Effect of exchange rate changes15,333 — (9,147)— 
Projected benefit obligations at end of year$132,279 $91,185 $212,120 $90,293 
Change in plan assets:
Fair value of plan assets at beginning of year$93,500 $91,777 $112,305 $202,331 
Actual return on plan assets— 7,965 (9,513)6,702 
Benefits paid and plan expenses(8,045)(9,571)(14,770)(20,986)
Employer’s contributions8,045 — 7,066 — 
Refund of annuity purchase premium— 2,147 — — 
Plan settlements(89,351)— — (96,270)
Excess plan assets returned to the employer(3,271)— — — 
Effect of exchange rate changes(878)— (1,588)— 
Fair value of plan assets at end of year$— $92,318 $93,500 $91,777 
Net (liabilities) assets recognized in the consolidated balance sheets$(132,279)$1,133 $(118,620)$1,484 
Net amounts recognized in the consolidated balance sheets consist of:
Other assets$— $1,133 $7,552 $1,484 
Current liabilities(7,962)— (7,099)— 
Long-term liabilities(124,317)— (119,073)— 
Net (liabilities) assets recognized in the consolidated balance sheets$(132,279)$1,133 $(118,620)$1,484 
Actuarial assumptions as of the year-end measurement date:
Discount rate3.90 %5.29 %4.19 %5.71 %
Rate of compensation increase3.18 %None3.19 %None
Actuarial assumptions used to determine net periodic pension cost during the year were as follows:
December 28, 2025December 29, 2024December 31, 2023
Non-U.S.U.S.Non-U.S.U.S.Non-U.S.U.S.
Discount rate4.19 %5.71 %3.69 %4.54 %4.12 %4.84 %
Rate of compensation increase3.19 %None3.19 %None3.16 %None
Expected rate of return on assetsNone4.60 %3.78 %4.60 %3.92 %4.80 %
 
The Company’s expected rate of return on assets assumptions are derived from management’s estimates, as well as other information compiled by management, including studies that utilize customary procedures and techniques. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study gives appropriate consideration to recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate.
The Company’s discount rate assumptions are derived from a range of factors, including a yield curve for certain plans, composed of the rates of return on high-quality fixed-income corporate bonds available at the measurement date and the related expected duration for the obligations, and a bond matching approach for certain plans.
The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets:
December 28,
2025		December 29,
2024
(In thousands)
Pension Plans with Projected Benefit Obligations in Excess of Plan Assets
Projected benefit obligations$132,279 $126,172 
Fair value of plan assets— — 
Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets
Accumulated benefit obligations$132,279 $126,172 
Fair value of plan assets— — 
 Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 28, 2025 and December 29, 2024, and target asset allocations for fiscal year 2026 are as follows:
 Target AllocationPercentage of Plan Assets at
January 3, 2027December 28, 2025December 29, 2024
Asset CategoryU.S.U.S.Non-U.S.U.S.
Equity securities0-10%5 %— %5 %
Debt securities90-100%95 %— %95 %
Other0-10%— %100%— %
Total100 %100 %100 %100 %
The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans which are designed to maximize the total rate of return (income and appreciation) after inflation within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments.
The target allocations for plan assets are listed in the above table. Equity securities primarily include investments in mutual funds with holdings in large-cap and mid-cap companies located in the United States and abroad. Debt securities include corporate bonds of companies from diversified industries, high-yield bonds, and U.S. government securities. Other types of investments include investments in non-U.S. government index linked bonds, multi-strategy hedge funds, venture capital funds and foreign liability driven investments that follow several different strategies.
The fair value of the Company’s pension plan assets as of December 28, 2025 and December 29, 2024 by asset category, classified in the three levels of inputs described in Note 20, Fair Value Measurements, are as follows:
 
 
Fair Value Measurements at December 28, 2025 Using:
Total Carrying
Value at
December 28, 2025
Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash and cash equivalents$615 $615 $— $— 
Equity securities:
U.S. large-cap2,833 2,833 — — 
International large-cap value1,149 1,149 — — 
Emerging markets growth484 484 — — 
Fixed income securities:
Corporate and U.S. debt instruments87,237 — 87,237 — 
Total assets measured at fair value$92,318 $5,081 $87,237 $— 
 
Fair Value Measurements at December 29, 2024 Using:
Total Carrying
Value at
December 29, 2024
Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash$7,555 $7,555 $— $— 
Equity securities:
U.S. large-cap3,049 3,049 — — 
International large-cap value887 887 — — 
Emerging markets growth403 403 — — 
Fixed income securities:
Corporate and U.S. debt instruments83,267 25,905 57,362 — 
Corporate bonds1,630 — 1,630 — 
Other types of investments:
Foreign liability driven instrument88,486 — — 88,486 
Total assets measured at fair value$185,277 $37,799 $58,992 $88,486 

Valuation Techniques: Valuation techniques utilized need to maximize the use of observable inputs and minimize the use of unobservable inputs. There have been no changes in the methodologies utilized at December 28, 2025 compared to December 29, 2024. The following is a description of the valuation techniques utilized to measure the fair value of the assets shown in the table above.

Equity Securities: Mutual funds held by the Master Trust are open‑ended mutual funds that are registered with the U.S. Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Master Trust are deemed to be actively traded. These are categorized as Level 1 assets.

Fixed Income Securities: Fixed income U.S. government bonds are valued at quoted market prices and are categorized as Level 1 assets.
Fixed income corporate bond exchange traded funds or individual fixed income corporate bonds are categorized as Level 2 assets except where sufficient quoted prices exist in active markets, in which case such securities are categorized as Level 1 assets. These securities are valued using third-party pricing services. These services may use, for example, model-based pricing methods that utilize observable market data as inputs. Broker dealer bids or quotes of securities with similar characteristics may also be used.
Other Types of Investments:   In September 2021, the Company’s UK pension plan executed a buy-in contract with Phoenix Life LTD (“Phoenix”), under which the Company made an upfront payment to Phoenix in exchange for Phoenix’s agreement to make the benefit payments under the Company’s UK pension plan due to specified participants and their beneficiaries, thus transferring most of the investment and longevity risk associated with the covered participants and beneficiaries from the Company to Phoenix. This buy-in contract was considered a liability-driven investment (“LDI”) solution. These were categorized as Level 3 assets.
The Company’s policy is to recognize significant transfers between levels at the actual date of the event.
A reconciliation of the beginning and ending Level 3 investments is as follows:
 
(In thousands)
Balance at December 31, 2023$100,666 
Pension benefits paid(6,216)
Foreign exchange losses(1,237)
Return on plan assets(4,727)
Balance at December 29, 202488,486 
Foreign exchange losses(831)
Settlement of plan obligation(87,655)
Balance at December 28, 2025
$— 
 
With respect to plans outside of the United States, the Company expects to contribute $7.9 million in the aggregate during fiscal year 2026.
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
 
Non-U.S.U.S.
(In thousands)
2026$7,962 $8,458 
20277,980 8,409 
20288,053 8,345 
20297,819 8,202 
20308,046 8,027 
2031-2035
39,113 35,989 
 
The Company also sponsors a supplemental executive retirement plan to provide senior management with benefits in excess of normal pension benefits. Effective July 31, 2000, this plan was closed to new entrants. At December 28, 2025 and December 29, 2024, the projected benefit obligations were each $16.4 million. Assets with a fair value of $0.1 million and $0.6 million, segregated in a trust (which is included in marketable securities in the Other assets, net, on the consolidated balance sheets), were available to meet this obligation as of December 28, 2025 and December 29, 2024, respectively. Pension income and expenses for this plan netted to expense of $1.8 million in fiscal year 2025, income of $0.3 million in fiscal year 2024 and expense of $1.5 million in fiscal year 2023.
 
Post-retirement Medical Plan:  The Company provides healthcare benefits for eligible retired U.S. employees under a comprehensive major medical plan or under health maintenance organizations where available. Eligible U.S. employees qualify for retiree health benefits if they retire directly from the Company and have at least ten years of service. Generally, the major medical plan pays stated percentages of covered expenses after a deductible is met and takes into consideration payments by other group coverage and by Medicare. The plan requires retiree contributions under most circumstances and has provisions for cost-sharing charges. Effective January 1, 2000, this plan was closed to new hires. For employees retiring after 1991, the Company has capped its medical premium contribution based on employees’ years of service. The Company funds the amount allowable under a 401(h) provision in the Company’s defined benefit pension plan. Assets of the plan are primarily equity and debt securities and are available only to pay retiree health benefits. The costs of this plan are not material and the net assets in the plan totaled $21.2 million and $19.2 million at December 28, 2025 and December 29, 2024, respectively.
v3.25.4
Contingencies
 12 Months Ended
Dec. 28, 2025
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $10.8 million and $14.2 million as of December 28, 2025 and December 29, 2024, respectively, in accrued expenses and other current liabilities, which represents its management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. The Company’s environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded.
The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities, including product liability claims. Legal defense costs are recognized as incurred, and insurance recoveries are recognized when collection is probable. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at the reporting date, the total cost of resolving these contingencies at December 28, 2025 should not have a material adverse effect on the Company’s consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.
v3.25.4
Stock Plans
 12 Months Ended
Dec. 28, 2025
Share-Based Payment Arrangement [Abstract]  
Stock Plans Stock Plans
Stock-Based Compensation:
 The Company’s 2019 Incentive Plan (the “2019 Plan”) authorizes the issuance of stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and cash awards as part of the Company’s compensation programs. The 2019 Plan replaced the Company’s 2009 Incentive Plan (the “2009 Plan”). Upon shareholder approval of the 2019 Plan, 6.25 million shares of the Company’s common stock, as well as shares of the Company’s common stock previously granted under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price subject to a contractual repurchase right, became available for grant under the 2019 Plan. Awards granted under the 2009 Plan prior to its expiration remain outstanding. As part of the Company’s compensation programs, the Company also offers shares of its common stock under its Employee Stock Purchase Plan.
 The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units and stock grants, included in the Company’s consolidated statements of operations:
 December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Cost of product and service revenue$2,149 $2,495 $4,224 
Research and development expenses1,577 3,863 5,276 
Selling, general and administrative expenses19,121 31,451 31,910 
Total stock-based compensation expense$22,847 $37,809 $41,410 
The total income tax benefit recognized in the consolidated statements of operations for stock-based compensation was $5.3 million in fiscal year 2025, $8.0 million in fiscal year 2024 and $10.6 million in fiscal year 2023. Stock-based compensation costs capitalized as part of inventory were immaterial in all periods presented.
Stock Options:    The Company has granted options to purchase common shares at prices equal to the market price of the common shares on the date the option is granted. Conditions of vesting are determined at the time of grant. Options are generally exercisable in equal annual installments over a period of three years, and will generally expire seven years after the date of grant. Options replaced in association with business combination transactions are generally issued with the same terms of the respective plans under which they were originally issued.
The fair value of each option grant is estimated using the Black-Scholes option pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical and implied volatility of the Company’s stock. The average expected life was based on the contractual term of the option and historic exercise experience. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended:
 
December 28,
2025		December 29,
2024		December 31,
2023
Risk-free interest rate4.0 %4.1 %4.1 %
Expected dividend yield0.3 %0.3 %0.2 %
Expected lives5 years5 years5 years
Expected stock volatility33.2 %33.6 %32.7 %
The following table summarizes stock option activity for the fiscal year ended December 28, 2025:
 
 Number of SharesWeighted-Average Exercise Price
 (In thousands)
Outstanding at beginning of year1,160 $130.50 
Granted371 105.16 
Exercised(37)82.16 
Canceled(16)142.15 
Forfeited(16)116.30 
Outstanding at end of year1,462 $125.32 
Exercisable at end of year855 $138.29 
 The aggregate intrinsic value for outstanding and exercisable stock options at December 28, 2025 was $1.0 million with a weighted-average remaining contractual term of 2.6 years. At December 28, 2025, there were 1.5 million outstanding stock options that were vested and expected to vest in the future, with an aggregate intrinsic value of $2.2 million and a weighted-average remaining contractual term of 4.0 years.
 The weighted-average grant-date fair value of options granted during fiscal years 2025, 2024 and 2023 was $37.10, $37.85, and $45.18 per share, respectively. The total intrinsic value of options exercised during fiscal years 2025, 2024 and 2023 was $1.4 million, $4.9 million, and $2.4 million, respectively. Cash received from option exercises for fiscal years 2025, 2024 and 2023 was $2.9 million, $7.7 million, and $4.3 million, respectively. The total compensation expense recognized related to the Company’s outstanding options was $9.2 million in fiscal year 2025, $9.8 million in fiscal year 2024 and $9.1 million in fiscal year 2023.
There was $15.4 million of total unrecognized compensation cost related to nonvested stock options granted as of December 28, 2025. This cost is expected to be recognized over a weighted-average period of 2.0 years.
Restricted Stock Awards:    The Company has awarded shares of restricted stock and restricted stock units to certain employees and non-employee directors at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued employment. The fair value of the award at the time of the grant is expensed on a straight-line basis primarily in selling, general and administrative expenses over the vesting period, which is generally 3 years. Recipients of the restricted stock have the right to vote such shares and receive dividends.
 
The following table summarizes restricted stock award activity for the fiscal year ended December 28, 2025:
Number of
Shares		Weighted-Average Grant-Date Fair Value
 (In thousands)
Nonvested at beginning of year275 $122.80 
Granted197 109.71 
Vested(122)131.16 
Forfeited(21)112.40 
Nonvested at end of year329 $112.56 
 The fair value of restricted stock awards vested during fiscal years 2025, 2024 and 2023 was $16.0 million, $30.9 million, and $31.5 million, respectively. The total compensation expense recognized related to the restricted stock awards was $16.4 million in fiscal year 2025, $22.3 million in fiscal year 2024 and $28.3 million in fiscal year 2023.
 As of December 28, 2025, there was $20.3 million of total unrecognized compensation cost, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.8 years.
Employee Stock Purchase Plan:
In April 1999, the Company’s shareholders approved the 1998 Employee Stock Purchase Plan. In April 2005, the Compensation and Benefits Committee of the Company’s Board of Directors (the “Board”) voted to amend the Employee Stock Purchase Plan, effective July 1, 2005, whereby participating employees have the right to purchase common stock at a price equal to 95% of the closing price on the last day of each six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee’s voluntary contribution, which may not exceed 10% of the employee’s base compensation. During fiscal year 2025, the Company issued 27,111 shares of common stock under the Company’s Employee Stock Purchase Plan at a weighted-average price of $98.14 per share. During fiscal year 2024, the Company issued 14,339 shares under this plan at a weighted-average price of $99.62 per share. During fiscal year 2023, the Company issued 28,899 shares under this plan at a weighted-average price of $108.37 per share. At December 28, 2025, there remains available for sale to employees an aggregate of 0.6 million shares of the Company’s common stock out of the 5.0 million shares authorized by shareholders for issuance under this plan.
v3.25.4
Stockholders' Equity
 12 Months Ended
Dec. 28, 2025
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ Equity
Comprehensive Income:
The components of accumulated other comprehensive (loss) income consisted of the following:
 
Foreign
Currency
Translation
Adjustment,
net of tax		Unrecognized
Prior Service
Costs, net of
tax		Unrealized
(Losses)
Gains on
Securities,
net of tax		Accumulated
Other
Comprehensive
(Loss) Income
 (In thousands)
Balance, January 1, 2023$(446,664)$(798)$(35)$(447,497)
Current year change80,172 — (181)79,991 
Reclassification to retained earnings90,814 — — 90,814 
Balance, December 31, 2023(275,678)(798)(216)(276,692)
Current year change(119,260)— (153)(119,413)
Balance, December 29, 2024(394,938)(798)(369)(396,105)
Current year change173,876 — 94 173,970 
Balance, December 28, 2025
$(221,062)$(798)$(275)$(222,135)
The unrealized foreign exchange (gains) losses, net of income taxes, on intercompany debt for which repayment is not anticipated in the foreseeable future that was recorded in AOCI for the fiscal years 2025, 2024 and 2023 were $(165.3) million, $(0.9) million and $11.3 million, respectively.
Income taxes related to foreign currency translation adjustments recognized in AOCI during fiscal year 2025 were $59.5 million. Income taxes related to foreign currency translation adjustments recognized in AOCI during fiscal years 2024 and 2023 were not material.
Stock Repurchases:
On October 24, 2024, the Board authorized the Company to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a stock repurchase program (the “Repurchase Program”). On October 23, 2025, the Repurchase Program was terminated by the Board and the Board authorized the Company to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a new stock repurchase program (the “New Repurchase Program”). The New Repurchase Program will expire on October 22, 2027 unless terminated earlier by the Board and may be suspended or discontinued at any time. During fiscal year 2025, the Company repurchased 7,264,299 shares of common stock under the Repurchase Program for an aggregate cost of $695.4 million. During fiscal year 2025, the Company repurchased 1,245,232 shares of common stock under the New Repurchase Program for an aggregate cost of $120.5 million. As of December 28, 2025, $879.5 million remained available for aggregate repurchases of shares under the New Repurchase Program.
Subsequent to fiscal year 2025, the Company repurchased 608,907 shares of common stock under the New Repurchase Program at an aggregate cost of $64.2 million.
In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company’s equity incentive plans. During fiscal year 2025, the Company repurchased 37,710 shares of common stock for this purpose at an aggregate cost of $4.2 million. During fiscal year 2024, the Company repurchased 86,484 shares of common stock for this purpose at an aggregate cost of $9.8 million. During fiscal year 2023, the Company repurchased 103,144 shares of common stock for this purpose at an aggregate cost of $13.1 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.
 
Dividends:
The Board declared a regular quarterly cash dividend of $0.07 per share in each quarter of fiscal years 2025, 2024 and 2023, resulting in an annual cash dividends of $0.28 per share for fiscal years 2025, 2024 and 2023. At December 28, 2025, the Company had accrued $7.8 million for a dividend declared in October 23, 2025 for the fourth quarter of fiscal year 2025 that was paid in February 2026. On January 26, 2026, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year 2026 that will be payable in May 2026. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.
v3.25.4
Derivatives And Hedging Activities
 12 Months Ended
Dec. 28, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivatives and Hedging Activities Derivatives and Hedging Activities
 
The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business.
In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s consolidated statements of cash flows.
Principal hedged currencies include the Chinese Renminbi, British Pound, Euro and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling
$598.4 million at December 28, 2025 and $409.8 million at December 29, 2024, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of fiscal years 2025, 2024 and 2023.
During fiscal year 2018, the Company designated a portion of the 2026 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of December 28, 2025, the total notional amount of the 2026 Notes that was designated to hedge investments in foreign subsidiaries was €498.6 million. The unrealized foreign exchange losses (gains) recorded in AOCI related to the net investment hedge were $67.6 million, $(31.7) million and $19.5 million during the fiscal years 2025, 2024 and 2023, respectively.
The Company does not expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive income (loss) into interest and other expense, net within the next twelve months.
v3.25.4
Fair Value Measurements
 12 Months Ended
Dec. 28, 2025
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
 Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities, accounts receivable and notes receivable. The Company believes it had no significant concentrations of credit risk as of December 28, 2025.
 The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition and divestiture related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value.
 Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.
 The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 28, 2025 and December 29, 2024 classified in one of the three classifications described above:
 
 
Fair Value Measurements at December 28, 2025 Using:
 
Total Carrying
Value at December 28, 2025
Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$27,956 $27,956 $— $— 
Foreign exchange derivative assets1,832 — 1,832 — 
Foreign exchange derivative liabilities(1,487)— (1,487)— 
Contingent consideration asset14,890 — — 14,890 
Contingent consideration liability(17,869)— — (17,869)
 
Fair Value Measurements at December 29, 2024 Using:
 
Total Carrying
Value at December 29, 2024
Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$27,413 $27,413 $— $— 
Foreign exchange derivative assets861 — 861 — 
Foreign exchange derivative liabilities(1,048)— (1,048)— 
Contingent consideration asset14,890 — — 14,890 
Contingent consideration liability(21,753)— — (21,753)
 
Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities.
Marketable securities - available for sale: Includes equity and mutual fund investments measured at fair value using the quoted market prices in active markets at the reporting date.
Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company’s consolidated balance sheet on a net basis and are recorded in other assets. As of both December 28, 2025 and December 29, 2024, none of the master netting arrangements involved collateral.
Level 3 Valuation Techniques: The Company’s Level 3 assets and liabilities are comprised of contingent consideration related to the sale of the Business (see Note 3) and acquisitions. For assets and liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 assets and liabilities.
Contingent consideration:    Contingent consideration is measured at fair value at the disposition or acquisition date using projected milestone dates, discount rates, volatility, probabilities of success and projected achievement of financial targets, including revenues of the acquired business in many instances. Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model.
The fair value of the contingent consideration asset was initially measured using a lattice model and recognized upon the sale of the Business on March 13, 2023. In accordance with the terms of the sale of the Business, the Company is entitled to receive up to $150.0 million that is contingent on the exit valuation the buyer and its affiliated funds receive on a sale or other capital event related to the Business. Potential valuation adjustments may be made as additional information and market factors that impact the expected exit valuation of the Business becomes available, with the impact of such adjustments being recorded in the Company’s consolidated statements of operations. The Company recognized $15.9 million upon the sale of Business in fiscal year 2023. The change in fair value of $(1.0) million was recognized in selling, general and administrative expenses in fiscal year 2023. Adjustments to the fair value since initial recognition were not material. As of December 28, 2025 and December 29, 2024, the carrying value of the contingent consideration asset was $14.9 million.
The fair values of contingent consideration liability are calculated on a quarterly basis based on a collaborative effort of the Company’s operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving the revenue targets, with the impact of such adjustments being recorded in the consolidated statements of operations.
As of December 28, 2025, the Company may have to pay contingent consideration, related to acquisitions with open contingency periods that are substantially all revenue-based considerations, of up to $75.3 million. The expected maximum earnout period for acquisitions with open contingency period is 5.9 years from December 28, 2025, and the remaining weighted average expected earnout period at December 28, 2025 was 3.7 years.
A reconciliation of the beginning and ending Level 3 contingent consideration liabilities is as follows: 
 (In thousands)
Balance at January 1, 2023$(46,618)
Amounts paid and foreign currency translation9,741 
Change in fair value (included within selling, general and administrative expenses)(3,128)
Balance at December 31, 2023(40,005)
Amounts paid and foreign currency translation16,383 
Change in fair value (included within selling, general and administrative expenses)1,869 
Balance at December 29, 2024(21,753)
       Amounts paid and foreign currency translation2,484 
Change in fair value (included within selling, general and administrative expenses)1,400 
Balance at December 28, 2025$(17,869)
Financial Instruments Not Recorded at Fair Value
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1.
The Company’s outstanding senior unsecured notes had an aggregate fair value of $2,963.7 million and aggregate carrying value of $3,222.9 million as of December 28, 2025. The Company’s outstanding senior unsecured notes had an aggregate fair value of $2,765.5 million and aggregate carrying value of $3,151.5 million as of December 29, 2024. The fair values of the outstanding senior unsecured notes were estimated using market quotes from brokers and were based on current rates offered for similar debt, which are Level 2 measurements.
The Company’s other debt facilities, including the Company’s senior unsecured revolving credit facility, had an aggregate carrying value of $0.5 million as of December 29, 2024. The carrying value approximates fair value and were classified as Level 2.
v3.25.4
Leases (Notes)
 12 Months Ended
Dec. 28, 2025
Disclosure Text Block [Abstract]  
Leases [Text Block] Leases
Lessee Disclosures
The Company leases certain property and equipment under operating and finance leases. The Company’s leases have remaining lease terms of less than 1 year to 25 years, some of which include options to extend the lease for up to 5 years, and some of which include options to terminate the lease within 1 year. Finance leases are not material to the Company.
The components of lease expense were as follows:
 December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Operating lease cost$47,862 $40,957 $47,738 
Supplemental cash flow information related to leases was as follows:
 December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$37,179 $33,198 $42,597 
Right-of-use assets obtained in exchange for new lease obligations:
   Operating leases17,249 47,649 10,049 
Supplemental balance sheet information related to leases was as follows:
 December 28,
2025		December 29,
2024
 (In thousands, except lease term and discount rate)
Operating Leases:
Operating lease right-of-use assets$165,439 $167,716 
Operating lease liabilities included in Accrued expenses and other current liabilities$30,035 $23,582 
Operating lease liabilities148,108 151,505 
Total operating lease liabilities$178,143 $175,087 
Weighted Average Remaining Lease Term in Years
Operating leases7.38.2
Weighted Average Remaining Discount Rate
Operating leases4.9%4.7%
Lease costs from finance leases, short-term leases, variable lease costs and sub-lease income are not material.
Future payments of operating lease liabilities as of December 28, 2025 were as follows:
 (In thousands)
2026$37,328 
202735,369 
202829,214 
202923,760 
203020,094 
2031 and thereafter66,155 
Total lease payments211,920 
Less imputed interest(33,777)
    Total operating lease liabilities$178,143 
v3.25.4
Industry Segment and Geographic Area Information
 12 Months Ended
Dec. 28, 2025
Segment Reporting [Abstract]  
Industry Segment Information Segment and Geographic Area Information
The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The CODM of the Company is the Chief Executive Officer (“CEO”). The CEO evaluates the performance of its operating segments based on revenue and operating income as adjusted for certain items. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1.
Effective at the beginning of fiscal year 2025, the Company implemented changes to its operating model. The majority of the Company’s Applied Genomics business, previously reported as part of the Diagnostics segment, has been integrated into a newly formed Life Sciences Solutions business, encompassing all Life Sciences reagents and consumables, instruments and services, as well as technology and licensing, which is reported as part of the Life Sciences segment. Beginning in fiscal year 2025, the Life Sciences segment consists of Life Sciences Solutions and Software, while the Diagnostics segment consists of Immunodiagnostics and Reproductive Health.
The effect of the change is not significant. Prior period financial information has been reclassified to reflect this new segment composition for consistent comparison.
The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge
expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
The primary financial measure by which the Company evaluates the performance of its segments is adjusted operating income, which consists of operating income plus amortization of intangible assets, adjustments to operations arising from purchase accounting (primarily adjustments to the fair value of acquired inventory that are subsequently recognized), acquisition and divestiture-related costs, and other costs that are not expected to recur or are of a non-cash nature, primarily including restructuring actions, significant litigation matters and transformation costs. The CODM does not evaluate operating segments using discrete asset information and there are no segment assets reported to the CODM. Accordingly, no segment assets have been reported.
Revenue and operating income, including significant segment expenses, by reportable segment are shown in the table below for the fiscal years ended: 
December 28, 2025December 29, 2024December 31, 2023
Life
 Sciences		DiagnosticsTotalLife SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Segment revenue$1,431,104 $1,424,947 $2,856,051 $1,398,601 $1,356,425 $2,755,026 $1,458,192 $1,292,379 $2,750,571 
Segment cost of revenue516,297 633,769 488,188 576,162 510,445 548,612 
Segment selling, general and administrative expenses344,516 343,430 338,755 336,325 328,068 341,155 
Segment research and development expenses112,029 103,582 104,382 90,000 107,429 104,585 
Segment operating income$458,262 $344,166 802,428 $467,276 $353,938 821,214 $512,250 $298,027 810,277 
Corporate expenses(28,944)(41,754)(40,417)
Amortization of intangible assets(335,586)(359,376)(365,113)
Purchase accounting adjustments(1,248)79 (5,956)
Acquisition and divestiture-related costs(3,783)(25,379)(69,159)
Transformation costs(9,280)— — 
Asset impairment— (22,814)— 
Significant litigation matters and settlements(12,228)(7,775)(12)
Significant environmental matters1,208 — (2,457)
Restructuring and other, net(55,932)(17,454)(26,601)
Interest and other expense, net(88,358)(30,615)(117,586)
Income from continuing operations before income taxes$268,277 $316,126 $182,976 
Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:
 December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Life Sciences$33,485 $30,128 $30,110 
Diagnostics33,403 36,074 33,994 
Corporate2,867 2,271 2,551 
Total depreciation expense$69,755 $68,473 $66,655 
The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 28, 2025 and net long-lived assets based on physical location as of December 28, 2025 and December 29, 2024:
 Revenue
 December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
U.S.$1,126,274 $1,097,856 $1,117,654 
International:
China425,060 450,007 454,426 
Germany177,664 162,575 193,170 
United Kingdom126,849 112,883 125,419 
Other international1,000,204 931,705 859,902 
Total international1,729,777 1,657,170 1,632,917 
Total revenue$2,856,051 $2,755,026 $2,750,571 
 
 
Net Long-Lived Assets (a)
 December 28,
2025		December 29,
2024
 (In thousands)
U.S.$341,172 $348,868 
International:
Germany130,645 134,713 
United Kingdom40,839 35,097 
China34,894 49,207 
Other international201,481 177,995 
Total international407,859 397,012 
Total net long-lived assets$749,031 $745,880 
(a) Long-lived assets consist of property and equipment, net, operating lease right-of-use assets, rental equipment and other long-term assets.
v3.25.4
Subsequent Events
 12 Months Ended
Dec. 28, 2025
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Subsequent to fiscal year 2025, the Company completed its acquisition of Advanced Chemistry Development Inc. (“ACD/Labs”) for $72 million in cash paid at the closing and up to $8 million in contingent consideration to be paid in cash based on the achievement of certain revenue metrics through 2028. ACD/Labs is based in Toronto, Canada, has approximately 200 employees, and is a provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. ACD/Labs will be recognized in the Life Sciences segment.
v3.25.4
Insider Trading Arrangements
 3 Months Ended
Dec. 28, 2025
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
During the three months ended December 28, 2025, Anita Gonzales and Miriame Victor, each an officer for purposes of
Section 16 of the Securities Exchange Act of 1934, adopted a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408(a) of Regulation S-K.

 
Rule 10b5-1 Trading Arrangements
NamePositionTrading Arrangement Adoption DateDuration of Trading ArrangementAggregate Number of Securities to be Sold under the Trading Arrangement
Anita GonzalesVice President and Chief Accounting OfficerNovember 7, 2025April 20, 2026 -
November 6, 2026		Up to 249
Miriame VictorSenior Vice President, Chief Commercial OfficerNovember 26, 2025February 24, 2026 -
March 2, 2026		Up to 1,862
During the three months ended December 28, 2025, none of our directors or officers, for purposes of Section 16 of the Securities Exchange Act of 1934, adopted a “non-Rule 10b5-1 trading arrangement”, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as the terms are defined in Item 408(a) of Regulation S-K.
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.4
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 28, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Disclosures
 We have developed and maintain a Material Cyber Incident Disclosure Program. The program includes processes for the identification, review and assessment of materiality of cyber events, notification of our senior leadership and Board of Directors of such events, and financial reporting disclosures where applicable. As part of the program, we also engage in due diligence regarding the cybersecurity capabilities of our current and potential third-party vendors in accordance with industry best practices. Under the program, all material cyber incidents will be reported to our Board of Directors. The program is led by our Cyber Event Disclosure Committee, which includes members of our Information Security, Corporate Legal, External Reporting and Enterprise Risk Management teams. In addition to assessing our own cybersecurity preparedness, we also consider and evaluate cybersecurity risks associated with use of third-party service providers. Our Internal Audit team conducts an annual review of third-party hosted applications with a specific focus on any sensitive data shared with third parties. For all critical third party service provides, we perform a review of the vendor's System and Organization Controls (SOC), which is referred to as a SOC 1 or SOC 2 report. If a third-party vendor is not able to provide a SOC 1 or SOC 2 report, we take additional steps to understand and mitigate any additional risks. Our assessment of risks associated with use of third-party providers is part of our overall risk management framework. We have implemented comprehensive cybersecurity initiatives for our employees, including education, training, and testing. These measures are conducted at least annually to ensure our employees remain up-to-date with the latest security practices, complementing our continuously improving processes and systems.
Our Chief Information Security Officer (“CISO”) is responsible for developing and implementing our information security program. Our Information Security team monitors our exposure to external cybersecurity threats, leveraging automated tools and manual processes to ensure cybersecurity risk is effectively mitigated on a continuous basis. To achieve this, the Information Security team leverages internal IT resources, a managed security service provider, and additional third-party security software and technology services. When a specific incident has been identified, the Information Security team leverages our Cyber Incident Response Plan in conjunction with established Information Security policies to begin the assessment of the incident. Depending on the type and/or severity of the incident, our Information Security team will determine (in compliance with our Cyber Incident Response Plan) whether third party expertise or consultation is necessary. If such expertise or consultation is determined to be necessary, our Information Security and Corporate Legal teams will engage with third-party experts. As part of its review of incidents, our Information Security team considers the risk exposure, potential impact, severity and implications with respect to our information technology systems. Our CISO is responsible for escalating incidents which are determined to be higher risk to our Cyber Event Disclosure Committee. The Cyber Event Disclosure Committee will work with our General Counsel to determine the materiality of the incident and any required disclosure. When an incident is determined to be material and is required to be disclosed, the Cyber Event Disclosure Committee will notify our senior leadership and our Board of Directors through the Audit Committee of our Board of Directors. The Cyber Event Disclosure Committee will collaborate with our Corporate Legal and Financial Reporting teams to develop any required Form 8-K Item 1.05 disclosure.
The oversight, monitoring, and testing of the program occurs under our Sarbanes-Oxley entity-level control reviews and the program is integrated into our Enterprise Risk Management processes. The Cyber Event Disclosure Committee convenes, at least quarterly, to review recent developments in cybersecurity and in the cybersecurity risk landscape. The Cyber Event Disclosure Committee is comprised of representatives with relevant expertise for assessing and managing the applicable risks. Our Board of Directors is presented with updates on an annual, or as needed, basis regarding our cybersecurity preparedness. Additionally, at least annually, our Board of Directors is provided with a comprehensive cyber training from our CISO. Our Board of Directors annually reviews our cybersecurity program and the Audit Committee of our Board of Directors is specifically responsible for oversight of cybersecurity risk, which it regularly reviews with Company leadership.
We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations or financial condition.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations or financial condition.
Cybersecurity Risk Board of Directors Oversight [Text Block] Our CISO is responsible for escalating incidents which are determined to be higher risk to our Cyber Event Disclosure Committee. The Cyber Event Disclosure Committee will work with our General Counsel to determine the materiality of the incident and any required disclosure. When an incident is determined to be material and is required to be disclosed, the Cyber Event Disclosure Committee will notify our senior leadership and our Board of Directors through the Audit Committee of our Board of Directors. The Cyber Event Disclosure Committee will collaborate with our Corporate Legal and Financial Reporting teams to develop any required Form 8-K Item 1.05 disclosure.
The oversight, monitoring, and testing of the program occurs under our Sarbanes-Oxley entity-level control reviews and the program is integrated into our Enterprise Risk Management processes. The Cyber Event Disclosure Committee convenes, at least quarterly, to review recent developments in cybersecurity and in the cybersecurity risk landscape. The Cyber Event Disclosure Committee is comprised of representatives with relevant expertise for assessing and managing the applicable risks. Our Board of Directors is presented with updates on an annual, or as needed, basis regarding our cybersecurity preparedness. Additionally, at least annually, our Board of Directors is provided with a comprehensive cyber training from our CISO. Our Board of Directors annually reviews our cybersecurity program and the Audit Committee of our Board of Directors is specifically responsible for oversight of cybersecurity risk, which it regularly reviews with Company leadership.
Cybersecurity Risk Role of Management [Text Block] Our Board of Directors annually reviews our cybersecurity program
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cyber Event Disclosure Committee, which includes members of our Information Security, Corporate Legal, External Reporting and Enterprise Risk Management teams.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Our Information Security team monitors our exposure to external cybersecurity threats, leveraging automated tools and manual processes to ensure cybersecurity risk is effectively mitigated on a continuous basis. To achieve this, the Information Security team leverages internal IT resources, a managed security service provider, and additional third-party security software and technology services. When a specific incident has been identified, the Information Security team leverages our Cyber Incident Response Plan in conjunction with established Information Security policies to begin the assessment of the incident. Depending on the type and/or severity of the incident, our Information Security team will determine (in compliance with our Cyber Incident Response Plan) whether third party expertise or consultation is necessary. If such expertise or consultation is determined to be necessary, our Information Security and Corporate Legal teams will engage with third-party experts.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] The Cyber Event Disclosure Committee will work with our General Counsel to determine the materiality of the incident and any required disclosure. When an incident is determined to be material and is required to be disclosed, the Cyber Event Disclosure Committee will notify our senior leadership and our Board of Directors through the Audit Committee of our Board of Directors.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
v3.25.4
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Policies)
 12 Months Ended
Dec. 28, 2025
Accounting Policies [Abstract]  
Consolidation [Policy Text Block] The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Fiscal Periods [Policy Text Block]
The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a
52/53-week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 28, 2025 (“fiscal year 2025”), December 29, 2024 (“fiscal year 2024”) and December 31, 2023 (“fiscal year 2023”) included 52 weeks. The fiscal year ending January 3, 2027 (“fiscal year 2025”) will include 53 weeks.
Accounting Policies and Estimates [Policy Text Block]
Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Revenue Recognition [Policy Text Block]
Revenue Recognition: The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The Company recognizes revenue in an amount that reflects the consideration the Company expects to receive in exchange for the promised products or services when a performance obligation is satisfied by transferring control of those products or services to customers.
Taxes that are collected by the Company from a customer and assessed by a governmental authority, that are both imposed on and concurrent with a specific revenue-producing transaction, are excluded from revenue.
The Company reports shipping and handling revenue in revenue, to the extent it is billed to customers, and the associated costs in cost of product revenue.
Inventories [Policy Text Block]
Inventories: Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements.
Income Taxes [Policy Text Block]
Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not.
The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions. These reserves are based on a determination of whether a tax benefit taken by the Company in its tax filings is more likely than not to be sustained upon audit based on its technical merits. The tax benefit recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense.
The Company is subject to the Global Intangible Low Taxed Income (“GILTI”) tax in the U.S. The Company elected to treat taxes on future GILTI inclusions in U.S. taxable income as a current period expense when incurred.
The Company uses the portfolio approach for releasing income tax effects from accumulated other comprehensive income.
Property, Plant and Equipment [Policy Text Block]
Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings - 10 to 40 years; leasehold improvements - estimated useful life or remaining term of lease, whichever is shorter; machinery and equipment - 3 to 10 years; and capitalized internal-use software - 3 to 10 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed. The Company capitalizes certain qualified costs incurred in connection with the development of internal-use software. The Company evaluates the costs incurred during the application development stage of internal use software to determine whether the costs meet the criteria for capitalization. Costs related to preliminary project activities and post implementation activities are expensed as incurred.
Change in Accounting for Pension and Other Postretirement Benefits [Policy Text Block] Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company’s fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds.
Translation of Foreign Currencies [Policy Text Block] Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive income (“AOCI”), a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net
Business Combinations [Policy Text Block]
Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses. Measurement period adjustments are made in the period in which the amounts are determined, and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.
Goodwill and Other Intangible Assets [Policy Text Block]
Goodwill and Other Intangible Assets:  The Company’s intangible assets consist of (i) goodwill, which is not being amortized; and (ii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives.
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. The Company's annual goodwill impairment testing date is the later of November 1 or the first day of its eleventh fiscal month of each fiscal year. Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values.
Stock-Based Compensation [Policy Text Block]
Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model or the quoted price of the Company’s stock on the grant date. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The
determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock. The Company recognizes the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation.
Marketable Securities and Investments [Policy Text Block] Marketable Securities and Investments:  Investments in debt securities that are classified as available for sale are recorded at fair value with unrealized gains and losses included in AOCI until realized. Investments in debt securities that are classified as held-to-maturity are recorded at amortized cost. Investments in equity securities are recorded at fair values with unrealized holding gains and losses included in earnings. Investments in equity securities without a readily determinable fair values are carried at cost minus impairment, if any. When an observable price change in orderly transactions for the identical or a similar investment of the same issuer has occurred, the Company elects to carry those equity investments at fair value as of the date that the observable transaction occurred.
Cash Flows [Policy Text Block]
Cash and Cash Equivalents: The Company considers all highly liquid, unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.
Environmental Matters [Policy Text Block]
Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.
Research and Development Expense, Policy [Policy Text Block] Research and Development: Research and development costs are expensed as incurred.
Restructuring Charges [Policy Text Block] Restructuring and Other Costs: Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period.
New Accounting Pronouncement or Change in Accounting Principle, Description
Comprehensive Income:  Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.
Derivative Instruments and Hedging [Policy Text Block]
Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting.
For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive income (loss) and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements.
The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]
Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
In December 2025, the FASB issued Accounting Standards Update 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities (“ASU 2025-10”), which establishes authoritative guidance on the recognition, measurement, presentation, and disclosure of government grants. Under ASU 2025-10, government grants are recognized when it is probable that the entity will both comply with the conditions of the grant and the grant will be received. ASU 2025-10 provides specific accounting models for grants related to assets and grants related to income, including options to recognize government grants as deferred income or as a reduction of the asset’s cost basis. ASU 2025-10 also requires enhanced disclosures regarding the nature of government grants, significant terms and conditions, accounting policies applied, and amounts recognized in the financial statements. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-10 but does not expect the impact of such adoption to be material.
In December 2025, the FASB issued Accounting Standards Update 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (“ASU 2025-11”), which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. ASU 2025-11 provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-11.
In September 2025, the FASB issued Accounting Standards Update 2025-06, Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”). ASU 2025-06 amends certain aspects of the accounting for and disclosure of software costs. The amendments in this update are effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The guidance may be applied prospectively, retrospectively, or via a modified prospective transition method. The Company is in the process of determining the impact of this guidance on its financial statements and disclosures.
In November 2024, the FASB issued Accounting Standards Update 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”). ASU 2024-03 requires public entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items. Such disclosures are required on an annual and interim basis in a tabular presentation in the footnotes to the financial statements. In addition, ASU 2024-03 requires public
entities to disclose selling expenses on an annual and interim basis. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is in the process of determining the impact of this guidance on its financial statements and disclosures.
In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 will require public entities to disclose on an annual basis a tabular reconciliation using both percentages and amounts, broken out into specific categories with certain reconciling items at or above 5% of the statutory (i.e. expected) tax further broken out by nature and/or jurisdiction. ASU 2023-09 requires all entities to disclose on an annual basis the amount of income taxes paid (net of refunds received), disaggregated between federal (national), state/local and foreign, and amounts paid to an individual jurisdiction when 5% or more of the total income taxes paid. The Company adopted the guidance in fiscal year 2025 on a prospective basis and has included the additional disclosures related to income taxes in Note 6, Income Taxes.
Lessee, Leases [Policy Text Block] Leases: Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets represent the Company’s right to use an
underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized based on the present value of the remaining lease payments over the lease term. When the Company’s lease did not provide an implicit rate, the Company used its incremental borrowing rate in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.
The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component.
The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statements of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred.
Lessor, Leases [Policy Text Block]
As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under Accounting Standards Codification 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with Accounting Standards Codification 842, Leases (“ASC 842”).
v3.25.4
Leases (Policies)
 12 Months Ended
Dec. 28, 2025
Leases [Abstract]  
Lessee, Leases [Policy Text Block] Leases: Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets represent the Company’s right to use an
underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized based on the present value of the remaining lease payments over the lease term. When the Company’s lease did not provide an implicit rate, the Company used its incremental borrowing rate in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.
The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component.
The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statements of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred.
Lessor, Leases [Policy Text Block]
As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under Accounting Standards Codification 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with Accounting Standards Codification 842, Leases (“ASC 842”).
v3.25.4
Revenue from Contract with Customer (Tables)
 12 Months Ended
Dec. 28, 2025
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue [Table Text Block]
In the following tables, revenue is disaggregated by primary geographical market and major good and service lines.
Reportable Segments
For the fiscal year ended
December 28, 2025December 29, 2024December 31, 2023
Life
 Sciences		DiagnosticsTotalLife SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$750,857 $505,104 $1,255,961 $745,206 $477,881 $1,223,087 $759,782 $455,831 $1,215,613 
Europe343,507 481,471 824,978 315,173 427,441 742,614 344,713 402,310 747,023 
Asia336,740 438,372 775,112 338,222 451,103 789,325 353,697 434,238 787,935 
$1,431,104 $1,424,947 $2,856,051 $1,398,601 $1,356,425 $2,755,026 $1,458,192 $1,292,379 $2,750,571 
Major goods/service lines
Life Sciences Solutions$1,194,728 $— $1,194,728 $1,197,802 $— $1,197,802 $1,279,903 $— $1,279,903 
Software236,376 — 236,376 200,799 — 200,799 178,289 — 178,289 
Immunodiagnostics— 869,908 869,908 — 828,627 828,627 — 787,394 787,394 
Reproductive health— 555,039 555,039 — 527,798 527,798 — 504,985 504,985 
$1,431,104 $1,424,947 $2,856,051 $1,398,601 $1,356,425 $2,755,026 $1,458,192 $1,292,379 $2,750,571 
v3.25.4
Discontinued Operations (Tables)
 12 Months Ended
Dec. 28, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The following table summarizes the results of discontinued operations which are presented as income from discontinued operations in the Company’s consolidated statements of operations:
 December 28, 2025December 29, 2024December 31, 2023
 (In thousands)
Revenue$— $— $176,324 
Cost of revenue— — 125,219 
Selling, general and administrative expenses— — 78,613 
Research and development expenses— — 10,434 
Operating loss— — (37,942)
Other (loss) income:
(Loss) gain on sale(817)(25,448)811,472 
Other expense, net— — (49)
Total other (loss) income(817)(25,448)811,423 
(Loss) income from discontinued operations before income taxes(817)(25,448)773,481 
(Benefit from) provision for income tax(2,135)(12,762)259,890 
Income (loss) from discontinued operations$1,318 $(12,686)$513,591 
Schedule of Operating and Investing non-cash items from discontinued operations [Table Text Block]
The capital expenditures from discontinued operations for the fiscal year 2023 were not material.
v3.25.4
Restructuring and Related Activities (Tables)
 12 Months Ended
Dec. 28, 2025
Restructuring Cost and Reserve [Line Items]  
Restructuring and Other Costs By Segment [Table Text Block]
Restructuring and other costs, included in the selling, general and administrative expenses in the consolidated statements of operations, by segment are as follows:
 
December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Life Sciences$15,552 $4,532 $6,203 
Diagnostics39,337 12,539 15,465 
Corporate1,043 383 4,933 
$55,932 $17,454 $26,601 
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]
The following table summarizes the changes in the Company’s accrued restructuring balance for fiscal year 2025. The changes in accrued restructuring balance for fiscal years 2024 and 2023 were not material. Other amounts reported as restructuring and other costs during fiscal year 2025 in the accompanying statement of income have been summarized in the notes to the table. Remaining obligations related to these accounts are expected to be paid over the next 12 months and are included in the accrued expenses and other current liabilities in the consolidated balance sheets.
(In thousands)
Balance at December 29, 2024$3,836 
Net restructuring charges incurred in 2025 (a)
28,167 
Payments(14,210)
Balance at December 28, 2025$17,793 
(a) Excludes $27.8 million of charges, principally $20.8 million for asset impairment and $0.8 million of lease abandonment charges in the Diagnostics segment and $6.2 million of lease abandonment charges in the Life Sciences segment.
v3.25.4
Income Taxes (Tables) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Income Tax Disclosure [Abstract]    
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
As described in Note 1 above, the Company has elected to adopt the guidance in ASU 2023-09 on a prospective basis. A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision for the fiscal year ended December 28, 2025 is as follows:
AmountPercent
(In thousands)
Tax at statutory rate$56,338 21.0 %
Domestic state and local income taxes, net of federal effect (a)
(1,281)(0.5)
Foreign tax effects
China
Audit and dispute resolution4,390 1.6 
Other(2,780)(1.0)
Germany
Audit and dispute resolution(2,902)(1.1)
Rate change4,850 1.8 
State and local income taxes(4,045)(1.5)
Other(1,942)(0.7)
Other foreign jurisdictions3,978 1.5 
Tax credits
Foreign tax credits(30,208)(11.3)
Other(2,473)(0.9)
Nontaxable and nondeductible items
Effect of stock compensation4,943 1.8 
Other(575)(0.2)
Cross-border tax laws
Subpart F income5,217 1.9 
Foreign-derived intangible income(15,526)(5.8)
Other3,855 1.4 
Change in valuation allowance
8,644 3.2 
Other
(2,003)(0.6)
Worldwide changes in unrecognized tax benefits(86)— 
Provision for income tax at effective tax rate$28,394 10.6 %
(a) State taxes in California, Massachusetts and Pennsylvania made up the majority (greater than 50%) of the tax effect in this category.
 A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended:
December 29,
2024		December 31,
2023
(In thousands)
Tax at statutory rate$66,386 $38,346 
Non-U.S. rate differential, net(13,332)(18,479)
U.S. taxation of multinational operations(28,879)(4,594)
State income taxes, net2,174 (265)
Impact of rate changes— (12,795)
Prior year tax matters(9,389)3,971 
Effect of stock compensation2,960 2,225 
General business tax credits(17,634)(4,718)
Transfer pricing matters(2,391)(6,725)
Change in valuation allowance29,781 6,772 
Effect of foreign repatriations5,329 (4,737)
Other, net(1,950)4,472 
Provision for income taxes$33,055 $3,473 
  
Deferred tax assets, other assets, net $ 32,652 $ 5,613
Deferred tax liabilities, Long-term liabilities (487,254) (456,103)
Deferred Tax Liabilities, Net $ (454,602) $ (450,490)
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]
The amount of income taxes paid (net of refunds received) disaggregated by federal, state and foreign was as follows for the fiscal year ended December 28, 2025:  
(In thousands)
Federal$34,706 
State and local10,306 
Foreign
Germany14,636 
Finland23,957 
The Netherlands7,377 
Singapore16,300 
All other foreign24,068 
Total income taxes paid, net of refunds received$131,350 
  
v3.25.4
Earnings Per Share (Tables)
 12 Months Ended
Dec. 28, 2025
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended:
December 28,
2025		December 29,
2024		December 31,
2023
(In thousands)
Number of common shares—basic116,542 122,756 124,704 
Effect of dilutive securities:
Stock options15 57 108 
Restricted stock awards38 9 — 
Number of common shares—diluted116,595 122,822 124,812 
Number of potentially dilutive securities excluded from calculation due to antidilutive impact1,290 951 1,089 
v3.25.4
Accounts Receivable, Net Accounts Receivable, Net (Tables)
 12 Months Ended
Dec. 28, 2025
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
Accounts receivable, net consisted of the following:
 
December 28,
2025		December 29,
2024
(In thousands)
Accounts receivable, net$744,671 $632,400 
Long-term accounts receivable, net, included in Other assets, net38,008 28,163 
Total accounts receivable, net$782,679 $660,563 
Accounts Receivable, Allowance for Credit Loss
Reserves for credit losses consisted of the following:
Balance at Beginning of YearProvisionsCharges/
Write-offs
Other(1)
Balance at End
of Year
  (In thousands)
Year ended December 31, 2023$37,543 $9,067 $(3,559)$329 $43,380 
Year ended December 29, 202443,380 9,715 (4,487)(636)47,972 
Year ended December 28, 2025
47,972 2,476 (3,513)1,128 48,063 
v3.25.4
Inventories, Net (Tables)
 12 Months Ended
Dec. 28, 2025
Inventory Disclosure [Abstract]  
Schedule of Net Inventories
Inventories, net consisted of the following:
 
December 28,
2025		December 29,
2024
(In thousands)
Raw materials$173,033 $174,502 
Work in progress68,983 65,191 
Finished goods137,481 127,894 
Total inventories, net$379,497 $367,587 
v3.25.4
Property, Plant and Equipment, Net (Tables)
 12 Months Ended
Dec. 28, 2025
Property, Plant and Equipment, Net [Abstract]  
Property, Plant and Equipment [Table Text Block]
Property, plant and equipment consisted of the following:
December 28,
2025		December 29,
2024
(In thousands)
At cost:
Land$33,016 $29,521 
Building and leasehold improvements391,098 364,556 
Machinery and equipment534,711 486,614 
     Capitalized internal-use software134,309 101,193 
Total property, plant and equipment1,093,134 981,884 
Accumulated depreciation(613,885)(499,667)
Total property, plant and equipment, net$479,249 $482,217 
v3.25.4
Marketable Securities and Investments (Tables)
 12 Months Ended
Dec. 28, 2025
Marketable Securities [Abstract]  
Schedule of Investments, Noncurrent [Table Text Block] Investments consisted of the following:
 
December 28,
2025		December 29,
2024
(In thousands)
Marketable securities - available for sale$27,956 $27,413 
Equity investments49,814 56,170 
Notes receivables and other investments12,366 12,337 
$90,136 $95,920 
Equity Securities without Readily Determinable Fair Value Equity investments, which are included in Other assets, net, in the consolidated balance sheets, have no readily determinable fair values and are carried at cost less any impairment.
v3.25.4
Goodwill and Intangible Assets, Net (Tables)
 12 Months Ended
Dec. 28, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in the Carrying Amount of Goodwill
The changes in the carrying amount of goodwill for fiscal years 2025 and 2024 are as follows:
Life SciencesDiagnosticsConsolidated
(In thousands)
Balance at December 31, 2023$4,587,938 $1,945,612 $6,533,550 
Foreign currency translation(46,471)(23,460)(69,931)
Balance at December 29, 20244,541,467 1,922,152 6,463,619 
Foreign currency translation105,495 44,379 149,874 
Other98,000 (98,000)— 
Balance at December 28, 2025
$4,744,962 $1,868,531 $6,613,493 
Identifiable Intangible Asset Balances
Amortizable intangible asset balances at December 28, 2025 and December 29, 2024 were as follows:
December 28,
2025		December 29,
2024
(In thousands)
Patents$27,592 $27,808 
Less: Accumulated amortization(26,524)(26,293)
Net patents1,068 1,515 
Trade names and trademarks150,103 142,588 
Less: Accumulated amortization(102,234)(87,824)
Net trade names and trademarks47,869 54,764 
Licenses27,561 27,164 
Less: Accumulated amortization(19,849)(17,855)
Net licenses7,712 9,309 
Core technology1,624,925 1,561,831 
Less: Accumulated amortization(921,325)(735,532)
Net core technology703,600 826,299 
Customer relationships2,870,384 2,807,909 
Less: Accumulated amortization(1,283,630)(1,058,875)
Net customer relationships1,586,754 1,749,034 
Net amortizable intangible assets$2,347,003 $2,640,921 
v3.25.4
Debt (Tables)
 12 Months Ended
Dec. 28, 2025
Debt Disclosure [Abstract]  
Schedule of Maturities of Long-term Debt [Table Text Block]
The following table summarizes the maturities of the Company’s indebtedness as of December 28, 2025: 
(In thousands)
2026$589,450 
2027— 
2028500,000 
2029850,000 
2030— 
2031 and thereafter1,300,000 
Total debt payments$3,239,450 
Schedule of Debt The Company’s debt consisted of the following:
December 28, 2025
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(2,857)$(2,857)
1.900% Senior Unsecured Notes due in 2028 (“2028 Notes”)
500,000 (148)(1,791)498,061 
3.3% Senior Unsecured Notes due in 2029 (“2029 Notes”)850,000 (1,169)(3,235)845,596 
2.55% Senior Unsecured Notes due in March 2031 (“March 2031 Notes”)400,000 (75)(1,952)397,973 
2.250% Senior Unsecured Notes due in September 2031 (“September 2031 Notes”)
500,000 (919)(2,641)496,440 
3.625% Senior Unsecured Notes due in 2051 (“2051 Notes”)400,000 (3)(3,974)396,023 
Total Long-Term Debt2,650,000 (2,314)(16,450)2,631,236 
Current Portion of Long-Term Debt:
€500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”)
589,450 (343)(279)588,828 
Total Current Portion of Long-Term Debt589,450 (343)(279)588,828 
Total Debt$3,239,450 $(2,657)$(16,729)$3,220,064 
December 29, 2024
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(1,208)$(1,208)
2026 Notes521,700 (834)(780)520,086 
2028 Notes500,000 (200)(2,408)497,392 
2029 Notes850,000 (1,448)(4,010)844,542 
March 2031 Notes400,000 (88)(2,294)397,618 
September 2031 Notes500,000 (1,065)(3,059)495,876 
2051 Notes400,000 (4)(4,059)395,937 
Other Debt Facilities, non-current233 — — 233 
Total Long-Term Debt3,171,933 (3,639)(17,818)3,150,476 
Current Portion of Long-Term Debt:
Other Debt Facilities, current242 — — 242 
Total Current Portion of Long-Term Debt242 — — 242 
Total Debt$3,172,175 $(3,639)$(17,818)$3,150,718 
v3.25.4
Accrued Expenses and Other Current Liabilities (Tables)
 12 Months Ended
Dec. 28, 2025
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Schedule of Accrued Liabilities [Table Text Block]
Accrued expenses and other current liabilities consisted of the following:
 
December 28,
2025		December 29,
2024
(In thousands)
Payroll and incentives$71,406 $74,984 
Employee benefits48,128 44,183 
Deferred revenue160,194 140,212 
Federal, non-U.S. and state income taxes80,565 74,403 
Operating lease liabilities
30,035 23,582 
Other accrued operating expenses166,626 128,031 
Total accrued expenses and other current liabilities$556,954 $485,395 
v3.25.4
Employee Benefit Plans (Tables) - Pension Plans, Defined Benefit
 12 Months Ended
Dec. 28, 2025
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
Components of Net Periodic Benefit Cost (Credit) Net periodic pension cost for U.S. and non-U.S. plans included the following components for fiscal years ended:
December 28,
2025		December 29,
2024		December 31,
2023
(In thousands)
Service and administrative costs$3,253 $5,017 $5,736 
Interest cost9,398 17,008 19,585 
Expected return on plan assets(4,003)(12,899)(14,600)
Actuarial (gains) losses(5,188)1,188 9,341 
Net periodic pension cost$3,460 $10,314 $20,062 
Schedule of Net Funded Status
The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 28, 2025 and December 29, 2024.
 December 28, 2025December 29, 2024
Non-U.S.U.S.Non-U.S.U.S.
(In thousands)
Actuarial present value of benefit obligations:
Accumulated benefit obligations$132,279 $91,185 $212,120 $90,293 
Change in benefit obligations:
Projected benefit obligations at beginning of year$212,120 $90,293 $227,579 $208,505 
Service and administrative costs1,811 1,425 3,442 1,575 
Interest cost4,476 4,922 7,966 9,042 
Benefits paid and plan expenses(8,045)(8,717)(14,770)(20,986)
Plan settlements(89,351)— — (96,270)
Actuarial (gains) losses(4,065)3,262 (2,950)(11,573)
Effect of exchange rate changes15,333 — (9,147)— 
Projected benefit obligations at end of year$132,279 $91,185 $212,120 $90,293 
Change in plan assets:
Fair value of plan assets at beginning of year$93,500 $91,777 $112,305 $202,331 
Actual return on plan assets— 7,965 (9,513)6,702 
Benefits paid and plan expenses(8,045)(9,571)(14,770)(20,986)
Employer’s contributions8,045 — 7,066 — 
Refund of annuity purchase premium— 2,147 — — 
Plan settlements(89,351)— — (96,270)
Excess plan assets returned to the employer(3,271)— — — 
Effect of exchange rate changes(878)— (1,588)— 
Fair value of plan assets at end of year$— $92,318 $93,500 $91,777 
Net (liabilities) assets recognized in the consolidated balance sheets$(132,279)$1,133 $(118,620)$1,484 
Net amounts recognized in the consolidated balance sheets consist of:
Other assets$— $1,133 $7,552 $1,484 
Current liabilities(7,962)— (7,099)— 
Long-term liabilities(124,317)— (119,073)— 
Net (liabilities) assets recognized in the consolidated balance sheets$(132,279)$1,133 $(118,620)$1,484 
Actuarial assumptions as of the year-end measurement date:
Discount rate3.90 %5.29 %4.19 %5.71 %
Rate of compensation increase3.18 %None3.19 %None
Actuarial assumptions used to determine net periodic pension cost during the year were as follows:
December 28, 2025December 29, 2024December 31, 2023
Non-U.S.U.S.Non-U.S.U.S.Non-U.S.U.S.
Discount rate4.19 %5.71 %3.69 %4.54 %4.12 %4.84 %
Rate of compensation increase3.19 %None3.19 %None3.16 %None
Expected rate of return on assetsNone4.60 %3.78 %4.60 %3.92 %4.80 %
Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]
The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets:
December 28,
2025		December 29,
2024
(In thousands)
Pension Plans with Projected Benefit Obligations in Excess of Plan Assets
Projected benefit obligations$132,279 $126,172 
Fair value of plan assets— — 
Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets
Accumulated benefit obligations$132,279 $126,172 
Fair value of plan assets— — 
Schedule of Allocation of Plan Assets Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 28, 2025 and December 29, 2024, and target asset allocations for fiscal year 2026 are as follows:
 Target AllocationPercentage of Plan Assets at
January 3, 2027December 28, 2025December 29, 2024
Asset CategoryU.S.U.S.Non-U.S.U.S.
Equity securities0-10%5 %— %5 %
Debt securities90-100%95 %— %95 %
Other0-10%— %100%— %
Total100 %100 %100 %100 %
Schedule of Changes in Fair Value of Plan Assets
The fair value of the Company’s pension plan assets as of December 28, 2025 and December 29, 2024 by asset category, classified in the three levels of inputs described in Note 20, Fair Value Measurements, are as follows:
 
 
Fair Value Measurements at December 28, 2025 Using:
Total Carrying
Value at
December 28, 2025
Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash and cash equivalents$615 $615 $— $— 
Equity securities:
U.S. large-cap2,833 2,833 — — 
International large-cap value1,149 1,149 — — 
Emerging markets growth484 484 — — 
Fixed income securities:
Corporate and U.S. debt instruments87,237 — 87,237 — 
Total assets measured at fair value$92,318 $5,081 $87,237 $— 
 
Fair Value Measurements at December 29, 2024 Using:
Total Carrying
Value at
December 29, 2024
Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
(In thousands)
Cash$7,555 $7,555 $— $— 
Equity securities:
U.S. large-cap3,049 3,049 — — 
International large-cap value887 887 — — 
Emerging markets growth403 403 — — 
Fixed income securities:
Corporate and U.S. debt instruments83,267 25,905 57,362 — 
Corporate bonds1,630 — 1,630 — 
Other types of investments:
Foreign liability driven instrument88,486 — — 88,486 
Total assets measured at fair value$185,277 $37,799 $58,992 $88,486 
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets
A reconciliation of the beginning and ending Level 3 investments is as follows:
 
(In thousands)
Balance at December 31, 2023$100,666 
Pension benefits paid(6,216)
Foreign exchange losses(1,237)
Return on plan assets(4,727)
Balance at December 29, 202488,486 
Foreign exchange losses(831)
Settlement of plan obligation(87,655)
Balance at December 28, 2025
$— 
Schedule of Expected Benefit Payments
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
 
Non-U.S.U.S.
(In thousands)
2026$7,962 $8,458 
20277,980 8,409 
20288,053 8,345 
20297,819 8,202 
20308,046 8,027 
2031-2035
39,113 35,989 
v3.25.4
Stock Plans (Tables)
 12 Months Ended
Dec. 28, 2025
Share-Based Payment Arrangement [Abstract]  
Summary of Total Compensation Recognized Related to Outstanding Equity Awards The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units and stock grants, included in the Company’s consolidated statements of operations:
 December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Cost of product and service revenue$2,149 $2,495 $4,224 
Research and development expenses1,577 3,863 5,276 
Selling, general and administrative expenses19,121 31,451 31,910 
Total stock-based compensation expense$22,847 $37,809 $41,410 
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended:
 
December 28,
2025		December 29,
2024		December 31,
2023
Risk-free interest rate4.0 %4.1 %4.1 %
Expected dividend yield0.3 %0.3 %0.2 %
Expected lives5 years5 years5 years
Expected stock volatility33.2 %33.6 %32.7 %
Summary of Stock Option Activity
The following table summarizes stock option activity for the fiscal year ended December 28, 2025:
 
 Number of SharesWeighted-Average Exercise Price
 (In thousands)
Outstanding at beginning of year1,160 $130.50 
Granted371 105.16 
Exercised(37)82.16 
Canceled(16)142.15 
Forfeited(16)116.30 
Outstanding at end of year1,462 $125.32 
Exercisable at end of year855 $138.29 
Summary of Restricted Stock Award Activity
The following table summarizes restricted stock award activity for the fiscal year ended December 28, 2025:
Number of
Shares		Weighted-Average Grant-Date Fair Value
 (In thousands)
Nonvested at beginning of year275 $122.80 
Granted197 109.71 
Vested(122)131.16 
Forfeited(21)112.40 
Nonvested at end of year329 $112.56 
v3.25.4
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 28, 2025
Stockholders' Equity Note [Abstract]  
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive (loss) income consisted of the following:
 
Foreign
Currency
Translation
Adjustment,
net of tax		Unrecognized
Prior Service
Costs, net of
tax		Unrealized
(Losses)
Gains on
Securities,
net of tax		Accumulated
Other
Comprehensive
(Loss) Income
 (In thousands)
Balance, January 1, 2023$(446,664)$(798)$(35)$(447,497)
Current year change80,172 — (181)79,991 
Reclassification to retained earnings90,814 — — 90,814 
Balance, December 31, 2023(275,678)(798)(216)(276,692)
Current year change(119,260)— (153)(119,413)
Balance, December 29, 2024(394,938)(798)(369)(396,105)
Current year change173,876 — 94 173,970 
Balance, December 28, 2025
$(221,062)$(798)$(275)$(222,135)
v3.25.4
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 28, 2025
Fair Value Disclosures [Abstract]  
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 28, 2025 and December 29, 2024 classified in one of the three classifications described above:
 
 
Fair Value Measurements at December 28, 2025 Using:
 
Total Carrying
Value at December 28, 2025
Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$27,956 $27,956 $— $— 
Foreign exchange derivative assets1,832 — 1,832 — 
Foreign exchange derivative liabilities(1,487)— (1,487)— 
Contingent consideration asset14,890 — — 14,890 
Contingent consideration liability(17,869)— — (17,869)
 
Fair Value Measurements at December 29, 2024 Using:
 
Total Carrying
Value at December 29, 2024
Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$27,413 $27,413 $— $— 
Foreign exchange derivative assets861 — 861 — 
Foreign exchange derivative liabilities(1,048)— (1,048)— 
Contingent consideration asset14,890 — — 14,890 
Contingent consideration liability(21,753)— — (21,753)
Reconciliation of Beginning and Ending Level 3 Net Liabilities
A reconciliation of the beginning and ending Level 3 contingent consideration liabilities is as follows: 
 (In thousands)
Balance at January 1, 2023$(46,618)
Amounts paid and foreign currency translation9,741 
Change in fair value (included within selling, general and administrative expenses)(3,128)
Balance at December 31, 2023(40,005)
Amounts paid and foreign currency translation16,383 
Change in fair value (included within selling, general and administrative expenses)1,869 
Balance at December 29, 2024(21,753)
       Amounts paid and foreign currency translation2,484 
Change in fair value (included within selling, general and administrative expenses)1,400 
Balance at December 28, 2025$(17,869)
v3.25.4
Leases (Tables)
 12 Months Ended
Dec. 28, 2025
Leases [Abstract]  
Lease, Cost [Table Text Block]
The components of lease expense were as follows:
 December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Operating lease cost$47,862 $40,957 $47,738 
Supplemental Cash Flow Information Related To Leases [Table Text Block]
Supplemental cash flow information related to leases was as follows:
 December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$37,179 $33,198 $42,597 
Right-of-use assets obtained in exchange for new lease obligations:
   Operating leases17,249 47,649 10,049 
Supplemental Balance Sheet Information Related To Leases [Table Text Block]
Supplemental balance sheet information related to leases was as follows:
 December 28,
2025		December 29,
2024
 (In thousands, except lease term and discount rate)
Operating Leases:
Operating lease right-of-use assets$165,439 $167,716 
Operating lease liabilities included in Accrued expenses and other current liabilities$30,035 $23,582 
Operating lease liabilities148,108 151,505 
Total operating lease liabilities$178,143 $175,087 
Weighted Average Remaining Lease Term in Years
Operating leases7.38.2
Weighted Average Remaining Discount Rate
Operating leases4.9%4.7%
Lease costs from finance leases, short-term leases, variable lease costs and sub-lease income are not material.
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
Future payments of operating lease liabilities as of December 28, 2025 were as follows:
 (In thousands)
2026$37,328 
202735,369 
202829,214 
202923,760 
203020,094 
2031 and thereafter66,155 
Total lease payments211,920 
Less imputed interest(33,777)
    Total operating lease liabilities$178,143 
v3.25.4
Industry Segment and Geographic Area Information (Tables)
 12 Months Ended
Dec. 28, 2025
Segment Reporting [Abstract]  
Schedule of Depreciation [Table Text Block]
Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:
 December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
Life Sciences$33,485 $30,128 $30,110 
Diagnostics33,403 36,074 33,994 
Corporate2,867 2,271 2,551 
Total depreciation expense$69,755 $68,473 $66,655 
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 28, 2025 and net long-lived assets based on physical location as of December 28, 2025 and December 29, 2024:
 Revenue
 December 28,
2025		December 29,
2024		December 31,
2023
 (In thousands)
U.S.$1,126,274 $1,097,856 $1,117,654 
International:
China425,060 450,007 454,426 
Germany177,664 162,575 193,170 
United Kingdom126,849 112,883 125,419 
Other international1,000,204 931,705 859,902 
Total international1,729,777 1,657,170 1,632,917 
Total revenue$2,856,051 $2,755,026 $2,750,571 
 
 
Net Long-Lived Assets (a)
 December 28,
2025		December 29,
2024
 (In thousands)
U.S.$341,172 $348,868 
International:
Germany130,645 134,713 
United Kingdom40,839 35,097 
China34,894 49,207 
Other international201,481 177,995 
Total international407,859 397,012 
Total net long-lived assets$749,031 $745,880 
v3.25.4
Business Combinations and Asset Purchases (Narrative) (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Business Combination [Line Items]      
Beginning balance $ 6,613,493 $ 6,463,619 $ 6,533,550
Diagnostics [Member]      
Business Combination [Line Items]      
Beginning balance $ 1,868,531 $ 1,922,152 $ 1,945,612
v3.25.4
Business Combinations and Asset Purchases (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Business Combination [Line Items]      
Goodwill $ 6,613,493 $ 6,463,619 $ 6,533,550
Diagnostics [Member]      
Business Combination [Line Items]      
Goodwill $ 1,868,531 $ 1,922,152 $ 1,945,612
v3.25.4
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Narrative) (Details) (Details)
 12 Months Ended
Jan. 03, 2027
Dec. 28, 2025
Fiscal Year Week Format   52
Subsequent Event [Member]    
Fiscal Year Week Format 53  
Building [Member] | Minimum [Member]    
Property, Plant and Equipment, Useful Life, Maximum   10 years
Building [Member] | Maximum [Member]    
Property, Plant and Equipment, Useful Life, Maximum   40 years
Tools, Dies and Molds [Member] | Minimum [Member]    
Property, Plant and Equipment, Useful Life, Maximum   3 years
Machinery and Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment, Useful Life, Maximum   10 years
v3.25.4
Revenue from Contract with Customer (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]      
Segment revenue $ 2,856,051 $ 2,755,026 $ 2,750,571
Unbilled Receivables 105,600 80,600  
Customer Deposits in Advance of Transfer of Control, Current 19,300 19,500  
Deferred Revenue $ 224,800 212,800  
Remaining Performance Obligations Transaction price allocated to the remaining performance obligationsThe Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.    
Americas [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue $ 1,255,961 1,223,087 1,215,613
Europe [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 824,978 742,614 747,023
Asia [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 775,112 789,325 787,935
Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 1,424,947 1,356,425 1,292,379
Diagnostics [Member] | Americas [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 505,104 477,881 455,831
Diagnostics [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 481,471 427,441 402,310
Diagnostics [Member] | Asia [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 438,372 451,103 434,238
Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 1,431,104 1,398,601 1,458,192
Life Sciences [Member] | Americas [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 750,857 745,206 759,782
Life Sciences [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 343,507 315,173 344,713
Life Sciences [Member] | Asia [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 336,740 338,222 353,697
Life Sciences Solutions [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 1,194,728 1,197,802 1,279,903
Life Sciences Solutions [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 0 0 0
Life Sciences Solutions [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 1,194,728 1,197,802 1,279,903
Software [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 236,376 200,799 178,289
Software [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 0 0 0
Software [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 236,376 200,799 178,289
Immunodiagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 869,908 828,627 787,394
Immunodiagnostics [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 869,908 828,627 787,394
Immunodiagnostics [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 0 0 0
Reproductive health [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 555,039 527,798 504,985
Reproductive health [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 555,039 527,798 504,985
Reproductive health [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue $ 0 $ 0 $ 0
v3.25.4
Discontinued Operations Narrative (Details) - USD ($)
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Mar. 13, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
(Benefit from) provision for income taxes on discontinued operations and dispositions $ (2,135,000) $ (12,762,000) $ 259,890,000  
Analytical, Food and Enterprise Services businesses        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
(Loss) gain on disposition of discontinued operations before income taxes (817,000) (25,448,000) 811,472,000  
(Benefit from) provision for income taxes on discontinued operations and dispositions (2,135,000) (12,762,000) $ 259,890,000  
Disposal Group, Consideration, Receivable at Closing, Deferred Payments Tied to Transfer of the PKI Brand and Related Trademarks       $ 75,000,000.0
Disposal Group, Consideration, Contingent on Exit Valuation       150,000,000.0
Disposal Group, Consideration, Cash Proceeds at Closing       $ 2,270,000,000
Disposal Group, Consideration, Brand Fee Tied to Transfer of the PKI Brand and Related Trademarks, Received During the Period $ 56,200,000 $ 18,800,000    
v3.25.4
Summary Operating Results of Discontinued Operations for the Periods Prior to Disposition (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Discontinued operations $ (2,135) $ (12,762) $ 259,890
Analytical, Food and Enterprise Services businesses      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Disposal Group, Including Discontinued Operation, Revenue 0 0 176,324
Disposal Group, Including Discontinued Operation, Costs of Goods Sold 0 0 125,219
Disposal Group, Including Discontinued Operation, General and Administrative Expense 0 0 78,613
Disposal Group, Including Discontinued Operations, Research and development expenses 0 0 10,434
Disposal Group, Including Discontinued Operation, Operating Income (Loss) 0 0 (37,942)
Income from discontinued operations before income taxes (817) (25,448) 773,481
(Loss) gain on disposition of discontinued operations before income taxes (817) (25,448) 811,472
Discontinued Operation, Other (Expense) Income, net 0 0 (49)
Discontinued Operation, Total Other (Expense) Income (817) (25,448) 811,423
Discontinued operations (2,135) (12,762) 259,890
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent $ 1,318 $ (12,686) $ 513,591
v3.25.4
Restructuring and Related Activities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Restructuring and Related Cost [Abstract]      
Restructuring And Other Costs (Income) Net $ 55,932 $ 17,454 $ 26,601
Other Charges Included in Restructuring and Other Costs $ 27,800    
Restructuring and Other Costs, Number of Positions Eliminated, Period Percent 5.00%    
Restructuring Reserve [Roll Forward] [Line Items]      
Restructuring Reserve, Beginning Balance $ 3,836    
Net restructuring charges incurred 28,167    
Payments for Restructuring (14,210)    
Restructuring Reserve, Ending Balance 17,793 3,836  
Life Sciences [Member]      
Restructuring and Related Cost [Abstract]      
Restructuring And Other Costs (Income) Net 15,552 4,532 6,203
Lease Abandonment Charges Included In Restructuring and Other Costs 6,200    
Diagnostics [Member]      
Restructuring and Related Cost [Abstract]      
Restructuring And Other Costs (Income) Net 39,337 12,539 15,465
Asset Impairment Charges Included in Restructuring and Other Costs 20,800    
Lease Abandonment Charges Included In Restructuring and Other Costs 800    
Corporate [Member]      
Restructuring and Related Cost [Abstract]      
Restructuring And Other Costs (Income) Net $ 1,043 $ 383 $ 4,933
v3.25.4
Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Income Tax Contingency [Line Items]      
Valuation Allowance, Amount $ 131,096 $ 126,488  
Unrecognized Tax Benefits [Roll Forward]      
Unrecognized tax benefits, beginning of period 149,785 129,056 $ 57,948
Gross increases - tax positions in prior period 1,638 29,623 64,697
Gross increases - current-period tax positions 0 0 14,969
Settlements (10,224) 0 0
Lapse of statute of limitations (3,046) (7,251) (10,830)
Foreign currency translation adjustments 4,361 (1,643) 2,272
Unrecognized tax benefits, end of period   149,785 129,056
Income Tax Penalties and Interest Accrued 4,500 5,100  
Income Tax Penalties and Interest Expense (Benefits) 300 (1,200) (1,100)
Unrecognized Tax Benefits, Ending Balance 142,514 149,785 129,056
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount   $ 5,329 $ (4,737)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount (4,600)    
General Business [Member]      
Unrecognized Tax Benefits [Roll Forward]      
Tax Credit Carryforward, Amount 33,200    
State and Local Jurisdiction [Member]      
Income Tax Contingency [Line Items]      
Operating Loss Carryforwards 2,300    
Unrecognized Tax Benefits [Roll Forward]      
Tax Credit Carryforward, Amount 6,100    
Foreign Tax Jurisdiction [Member]      
Income Tax Contingency [Line Items]      
Operating Loss Carryforwards 551,900    
Internal Revenue Service (IRS) [Member]      
Income Tax Contingency [Line Items]      
Operating Loss Carryforwards $ 102,600    
v3.25.4
Income Taxes Income Before Income taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Income Tax Contingency [Line Items]      
U.S. $ 142,633 $ 134,177 $ 51,314
Non-U.S. 125,644 181,949 131,662
Income from continuing operations before income taxes $ 268,277 $ 316,126 $ 182,976
v3.25.4
Income Taxes Components of the Provision (Benefits from) Income Tax (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Income Tax Contingency [Line Items]      
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount   $ (13,332) $ (18,479)
Federal current $ 12,257 42,708 39,800
Federal deferred expense (benefit) (14,468) (34,407) (60,845)
Federal total (2,211) 8,301 (21,045)
State current 10,328 17,040 9,183
State deferred expense (benefit) (8,659) (10,962) (19,619)
State total 1,669 6,078 (10,436)
Non-U.S. current 67,292 75,539 78,154
Non-U.S.deferred expense benefit (38,356) (56,863) (43,200)
Non-U.S. total 28,936 18,676 34,954
Total current 89,877 135,287 127,137
Total deferred expense (benefit) (61,483) (102,232) (123,664)
Total 28,394 33,055 3,473
Discontinued operations (2,135) (12,762) 259,890
Total provision for income taxes $ 26,259 $ 20,293 $ 263,363
v3.25.4
Income Taxes Reconciliation of Income Tax Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Income Tax Contingency [Line Items]      
Tax at statutory rate $ 56,338 $ 66,386 $ 38,346
Non-U.S. rate differential, net   (13,332) (18,479)
U.S. taxation of multinational operations   (28,879) (4,594)
State income taxes, net (1,281) 2,174 (265)
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount   0 (12,795)
Prior year tax matters   (9,389) 3,971
Effect of Stock Compensation   2,960 2,225
Federal tax credits   (17,634) (4,718)
Effective Income Tax Rate Reconciliation, Transfer Pricing Matters, Amount   (2,391) (6,725)
Change in valuation allowance 8,644 29,781 6,772
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount   5,329 (4,737)
Other, net (2,003) (1,950) 4,472
Total 28,394 33,055 3,473
Effective Income Tax Rate Reconciliation [Line Items]      
Tax at statutory rate 56,338 66,386 38,346
State income taxes, net (1,281) 2,174 (265)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount   (13,332) (18,479)
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount   0 (12,795)
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount (30,208)    
Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount (2,473)    
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount 4,943    
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount (575)    
Effective Income Tax Rate Reconciliation, Cross-border Tax Impact, Subpart F Income, Amount 5,217    
Effective Income Tax Rate Reconciliation, FDII, Amount (15,526)    
Effective Income Tax Rate Reconciliation, Cross-Border, Other, Amount 3,855    
Change in valuation allowance 8,644 29,781 6,772
Other, net (2,003) (1,950) 4,472
Income Tax Paid, Federal, after Refund Received 34,706    
Income Tax Paid, State and Local, after Refund Received 10,306    
Income Taxes Paid, Net 131,350    
Provision for income taxes 28,394 $ 33,055 $ 3,473
Worldwide changes in unrecognized tax benefits $ (86)    
Effective Income Tax Rate Reconciliation, Percent [Line Items]      
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00%    
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent (0.50%)    
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent (11.30%)    
Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent (0.90%)    
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent 1.80%    
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent (0.20%)    
Effective Income Tax Rate Reconciliation, Cross-border Tax Impact, Subpart F Income, Percent 1.90%    
Effective Income Tax Rate Reconciliation, FDII, Percent (5.80%)    
Effective Income Tax Rate Reconciliation, Cross-Border, Other, Percent 1.40%    
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 3.20%    
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent (0.60%)    
Effective Income Tax Rate Reconciliation, Worldwide changes in unrecognized tax benefits, Percent 0.00%    
Effective Income Tax Rate Reconciliation, Percent 10.60%    
Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration] CALIFORNIA, MASSACHUSETTS, PENNSYLVANIA    
CHINA      
Effective Income Tax Rate Reconciliation [Line Items]      
Effective Income Tax Rate Reconciliation, Foreign Tax Effects, Audit and Dispute Resolution, Amount $ 4,390    
Effective Income Tax Rate Reconciliation, Foreign Tax Effects, Other, Amount $ (2,780)    
Effective Income Tax Rate Reconciliation, Percent [Line Items]      
Effective Income Tax Rate Reconciliation, Foreign Tax Effects, Audit and Dispute Resolution, Percent 1.60%    
Effective Income Tax Rate Reconciliation, Foreign Tax Effects, Other, Percent (1.00%)    
GERMANY      
Income Tax Contingency [Line Items]      
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount $ 4,850    
Effective Income Tax Rate Reconciliation [Line Items]      
Effective Income Tax Rate Reconciliation, Foreign Tax Effects, Audit and Dispute Resolution, Amount (2,902)    
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 4,850    
Effective Income Tax Rate Reconciliation, Foreign Tax Effects, State and Local Income Taxes, Amount (4,045)    
Effective Income Tax Rate Reconciliation, Foreign Tax Effects, Other, Amount (1,942)    
Income Tax Paid, Foreign, after Refund Received $ 14,636    
Effective Income Tax Rate Reconciliation, Percent [Line Items]      
Effective Income Tax Rate Reconciliation, Foreign Tax Effects, Audit and Dispute Resolution, Percent (1.10%)    
Effective Income Tax Rate Reconciliation, Foreign Tax Effects, Other, Percent (0.70%)    
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent 1.80%    
Effective Income Tax Rate Reconciliation, Foreign Tax Effects, State and Local Income Taxes, Percent (1.50%)    
FINLAND      
Effective Income Tax Rate Reconciliation [Line Items]      
Income Tax Paid, Foreign, after Refund Received $ 23,957    
THE NETHERLANDS      
Effective Income Tax Rate Reconciliation [Line Items]      
Income Tax Paid, Foreign, after Refund Received 7,377    
SINGAPORE      
Effective Income Tax Rate Reconciliation [Line Items]      
Income Tax Paid, Foreign, after Refund Received 16,300    
Foreign Tax Jurisdiction, Other      
Income Tax Contingency [Line Items]      
Non-U.S. rate differential, net 3,978    
Effective Income Tax Rate Reconciliation [Line Items]      
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount 3,978    
Income Tax Paid, Foreign, after Refund Received $ 24,068    
Effective Income Tax Rate Reconciliation, Percent [Line Items]      
Effective Income Tax Rate Reconciliation, Foreign Tax Effects, Other, Percent 1.50%    
v3.25.4
Income Taxes Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Income Tax Contingency [Line Items]    
Inventory $ 11,879 $ 11,548
Reserves and accruals 80,623 70,544
Accrued compensation 19,554 23,637
Net operating loss and credit carryforwards 178,551 176,504
Accrued pension 11,800 12,773
Restructuring reserve 7,912 1,369
Deferred revenue 17,092 18,388
Deferred Tax Assets, Capitalized Research and Development Costs 46,511 69,208
Deferred Tax Assets, Unrealized Foreign Exchange Losses 0 2,612
Deferred tax assets, operating lease liabilities 31,335 33,468
All other, net 219 775
Deferred Tax Assets, Gross 405,476 420,826
Postretirement health benefits (5,540) (5,139)
Deferred Tax Liabilities, Unrealized Currency Transaction Gains (43,889) 0
Depreciation and amortization (621,045) (688,771)
Deferred Tax Liabilities, Prepaid Expenses (496) (375)
Deferred tax liability on foreign earnings (30,254) (19,662)
Deferred tax liabilities, operating lease right-of-use assets (27,758) (30,881)
Total deferred tax liabilities (728,982) (744,828)
Valuation allowance (131,096) (126,488)
Deferred Tax Liabilities, Net (454,602) $ (450,490)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ (4,600)  
v3.25.4
Income Taxes Summary of Loss and Tax Credit Carryforwards (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Income Tax Contingency [Line Items]    
Valuation Allowance, Amount $ 131,096 $ 126,488
State and Local Jurisdiction [Member]    
Income Tax Contingency [Line Items]    
Operating Loss Carryforwards 2,300  
Tax Credit Carryforward, Amount 6,100  
Foreign Tax Jurisdiction [Member]    
Income Tax Contingency [Line Items]    
Operating Loss Carryforwards 551,900  
Internal Revenue Service (IRS) [Member]    
Income Tax Contingency [Line Items]    
Operating Loss Carryforwards 102,600  
General Business [Member]    
Income Tax Contingency [Line Items]    
Tax Credit Carryforward, Amount $ 33,200  
v3.25.4
Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Earnings Per Share [Abstract]      
Number of common shares-basic 116,542 122,756 124,704
Effect of dilutive securities, Stock options 15 57 108
Effect of dilutive securities, Restricted stock 38 9 0
Number of common shares-diluted 116,595 122,822 124,812
Number of potentially dilutive securities excluded from calculation due to antidilutive impact 1,290 951 1,089
v3.25.4
Accounts Receivable, Net (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]      
Accounts receivable, net $ 744,671 $ 632,400  
Accounts Receivable, after Allowance for Credit Loss, Noncurrent 38,008 28,163  
Accounts Receivable, after Allowance for Credit Loss 782,679 660,563  
Accounts Receivable, Allowance for Credit Loss [Roll Forward]      
Accounts Receivable, Allowance for Credit Loss, Beginning Balance 47,972 43,380 $ 37,543
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 2,476 9,715 9,067
Accounts Receivable, Allowance for Credit Loss, Writeoff (3,513) (4,487) (3,559)
Accounts Receivable, Allowance for Credit Loss, Ending Balance 48,063 47,972 43,380
Allowance for Credit Loss [Abstract]      
Allowance for Credit Loss, Receivables, Other Period Activity $ 1,128 $ (636) $ 329
v3.25.4
Inventories, Net (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Inventory Disclosure [Abstract]    
Raw materials $ 173,033 $ 174,502
Work in progress 68,983 65,191
Finished goods 137,481 127,894
Total inventories $ 379,497 $ 367,587
v3.25.4
Property, Plant and Equipment, Net (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross $ 1,093,134 $ 981,884  
Accumulated depreciation (613,885) (499,667)  
Total property, plant and equipment, net 479,249 482,217  
Depreciation expense 69,755 68,473 $ 66,655
Asset Impairment Charges 4,784 22,814 0
Diagnostics [Member]      
Property, Plant and Equipment [Line Items]      
Depreciation expense 33,403 36,074 $ 33,994
Asset Impairment Related to Restructuring Actions Included in Selling General and Admin. 20,800    
Asset Impairment Related to Capitalized Internal-use Software Included in Selling General and Admin. 22,800    
Land [Member]      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 33,016 29,521  
Building and leasehold Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 391,098 364,556  
Capitalized internal-use software [Member]      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross 134,309 101,193  
Machinery and Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property, plant and equipment, gross $ 534,711 $ 486,614  
v3.25.4
Investments, Debt and Equity Securities (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Equity Securities without Readily Determinable Fair Value [Line Items]    
Marketable Securities, Noncurrent $ 27,956 $ 27,413
Equity Securities without Readily Determinable Fair Value, Amount 49,814 56,170
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount 31,300 31,300
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount 20,500 7,100
Notes Receivables and Other Investments, Notional Amount, Due Within One to Five Years 400  
Notes Receivables and Other Investments $ 12,366 $ 12,337
v3.25.4
Marketable Securities and Investments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]      
Marketable Securities, Noncurrent $ 27,956 $ 27,413  
Unrealized gains (losses) on securities, net of tax 94 (153) $ (181)
Marketable Securities and Investments 90,136 95,920  
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 13,300 2,100  
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount 20,500 7,100  
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount 31,300 31,300  
Notes Receivables and Other Investments, Notional Amount, Due Within One to Five Years 400    
Notes Receivables and Other Investments, Convertible to Equity Securities or are due and payable upon event of default, Notional Amount 12,000    
Credit Losses, included in Interest and other expense, net   1,800 $ 34,500
Notes Receivables and Other Investments $ 12,366 $ 12,337  
v3.25.4
Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Goodwill and Intangible Assets Net [Line Items]      
Total amortization expense related to finite-lived intangible assets $ 335,600 $ 359,400 $ 365,100
Future Amortization Expense, Year One 332,200    
Future Amortization Expense, Year Two 304,700    
Future Amortization Expense, Year Three 278,700    
Future Amortization Expense, Year Four 249,300    
Future Amortization Expense, Year Five 221,500    
Net amortizable intangible assets 2,347,003 2,640,921  
Beginning balance 6,613,493 6,463,619 6,533,550
Trade Names And Trademarks [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Net amortizable intangible assets 47,869 54,764  
Licenses [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Net amortizable intangible assets 7,712 9,309  
Diagnostics [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Beginning balance $ 1,868,531 $ 1,922,152 $ 1,945,612
v3.25.4
Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Changes in the carrying amount of goodwill    
Goodwill, Beginning Balance $ 6,463,619 $ 6,533,550
Foreign currency translation 149,874 (69,931)
Acquisitions, earn outs and other 0  
Ending balance 6,613,493 6,463,619
Life Sciences [Member]    
Changes in the carrying amount of goodwill    
Goodwill, Beginning Balance 4,541,467 4,587,938
Foreign currency translation 105,495 (46,471)
Acquisitions, earn outs and other 98,000  
Ending balance 4,744,962 4,541,467
Diagnostics [Member]    
Changes in the carrying amount of goodwill    
Goodwill, Beginning Balance 1,922,152 1,945,612
Foreign currency translation 44,379 (23,460)
Acquisitions, earn outs and other (98,000)  
Ending balance $ 1,868,531 $ 1,922,152
v3.25.4
Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Net amortizable intangible assets $ 2,347,003 $ 2,640,921
Intangible Assets, Net (Excluding Goodwill) 2,347,003 2,640,921
Patents [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 27,592 27,808
Less: Accumulated amortization (26,524) (26,293)
Net amortizable intangible assets 1,068 1,515
Trade Names And Trademarks [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 150,103 142,588
Less: Accumulated amortization (102,234) (87,824)
Net amortizable intangible assets 47,869 54,764
Licenses [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 27,561 27,164
Less: Accumulated amortization (19,849) (17,855)
Net amortizable intangible assets 7,712 9,309
Core Technology [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 1,624,925 1,561,831
Less: Accumulated amortization (921,325) (735,532)
Net amortizable intangible assets 703,600 826,299
Customer Relationships [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 2,870,384 2,807,909
Less: Accumulated amortization (1,283,630) (1,058,875)
Net amortizable intangible assets $ 1,586,754 $ 1,749,034
v3.25.4
Debt (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Jan. 07, 2025
Aug. 24, 2021
Unamortized Debt Issuance Expense $ (16,729) $ (17,818)      
Maturities of Long-term Debt [Abstract]          
2024 589,450        
2025 0        
2026 500,000        
2027 850,000        
2028 0        
2029 and Thereafter 1,300,000        
Long-term Debt Before Unamortized Discount 3,239,450        
Other Long-term Debt, Current 588,828 242      
Debt Instrument, Unamortized Discount (2,657) (3,639)      
Long-term Debt, Gross 2,650,000 3,171,933      
Debt, Long-term and Short-term, Combined Amount 3,239,450 3,172,175      
Current Portion of Long-Term Debt, Gross 589,450 242      
Current portion of long-term debt 588,828 242      
Proceeds from Sale and Maturity of Marketable Securities 0 710,000 $ 550,000    
Fair Value, Inputs, Level 2 [Member]          
Maturities of Long-term Debt [Abstract]          
Total (2,631,236) (3,150,476)      
Debt, Long-term and Short-term, Combined Amount 3,220,064 3,150,718      
Long-term Debt          
Unamortized Debt Issuance Expense (16,450) (17,818)      
Maturities of Long-term Debt [Abstract]          
Debt Instrument, Unamortized Discount (2,314) (3,639)      
Long-term Debt - Current Portion [Member]          
Unamortized Debt Issuance Expense (279) 0      
Maturities of Long-term Debt [Abstract]          
Debt Instrument, Unamortized Discount (343) 0      
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]          
Unamortized Debt Issuance Expense (3,235) (4,010)      
Maturities of Long-term Debt [Abstract]          
Debt Instrument, Unamortized Discount (1,169) (1,448)      
Long-term Debt, Gross 850,000 850,000      
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Fair Value, Inputs, Level 2 [Member]          
Maturities of Long-term Debt [Abstract]          
Total (845,596) (844,542)      
1.875 Percent Ten Year Senior Unsecured Notes [Member]          
Unamortized Debt Issuance Expense (279) (780)      
Maturities of Long-term Debt [Abstract]          
Debt Instrument, Unamortized Discount (343) (834)      
Long-term Debt, Gross   521,700      
Current Portion of Long-Term Debt, Gross 589,450        
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Fair Value, Inputs, Level 2 [Member]          
Maturities of Long-term Debt [Abstract]          
Total   (520,086)      
Current portion of long-term debt 588,828        
Line of Credit, Maturing August 24, 2026          
Unsecured revolving credit facility, amount         $ 1,500,000
Aggregate borrowings under the amended facility   0      
Unamortized Debt Issuance Expense   (1,208)      
Maturities of Long-term Debt [Abstract]          
Total   (1,208)      
Debt Instrument, Unamortized Discount   0      
Line of Credit, Maturing January 7, 2030          
Unsecured revolving credit facility, amount       $ 1,500,000  
Aggregate borrowings under the amended facility 0        
Unamortized Debt Issuance Expense (2,857)        
Maturities of Long-term Debt [Abstract]          
Total (2,857)        
Debt Instrument, Unamortized Discount $ 0        
Line of Credit, Maturing January 7, 2030 | Unsecured Revolving Credit Facility [Member] | Term Secured Overnight Financing Rate (SOFR) [Member]          
Maturities of Long-term Debt [Abstract]          
Debt Instrument, Basis Spread on Variable Rate 1.00%        
Line of Credit, Maturing January 7, 2030 | Unsecured Revolving Credit Facility [Member] | Federal Funds Rate [Member]          
Maturities of Long-term Debt [Abstract]          
Debt Instrument, Basis Spread on Variable Rate 0.50%        
1.900% Senior Unsecured Notes due 2028          
Unamortized Debt Issuance Expense $ (1,791) (2,408)      
Maturities of Long-term Debt [Abstract]          
Debt Instrument, Unamortized Discount (148) (200)      
Long-term Debt, Gross 500,000 500,000      
1.900% Senior Unsecured Notes due 2028 | Fair Value, Inputs, Level 2 [Member]          
Maturities of Long-term Debt [Abstract]          
Total (498,061) (497,392)      
2.55 Percent Senior Unsecured Notes due in 2031          
Unamortized Debt Issuance Expense (1,952) (2,294)      
Maturities of Long-term Debt [Abstract]          
Debt Instrument, Unamortized Discount (75) (88)      
Long-term Debt, Gross 400,000 400,000      
2.55 Percent Senior Unsecured Notes due in 2031 | Fair Value, Inputs, Level 2 [Member]          
Maturities of Long-term Debt [Abstract]          
Total (397,973) (397,618)      
2.250% Senior Unsecured Notes due in 2031          
Unamortized Debt Issuance Expense (2,641) (3,059)      
Maturities of Long-term Debt [Abstract]          
Debt Instrument, Unamortized Discount (919) (1,065)      
Long-term Debt, Gross 500,000 500,000      
2.250% Senior Unsecured Notes due in 2031 | Fair Value, Inputs, Level 2 [Member]          
Maturities of Long-term Debt [Abstract]          
Total (496,440) (495,876)      
3.625 Percent Senior Unsecured Notes due in 2051          
Unamortized Debt Issuance Expense (3,974) (4,059)      
Maturities of Long-term Debt [Abstract]          
Debt Instrument, Unamortized Discount (3) (4)      
Long-term Debt, Gross 400,000 400,000      
3.625 Percent Senior Unsecured Notes due in 2051 | Fair Value, Inputs, Level 2 [Member]          
Maturities of Long-term Debt [Abstract]          
Total $ (396,023) (395,937)      
Other Debt Facilities - Non-current          
Unamortized Debt Issuance Expense   0      
Maturities of Long-term Debt [Abstract]          
Other Long-term Debt, Noncurrent   233      
Debt Instrument, Unamortized Discount   0      
Other Debt Facilities - Non-current | Fair Value, Inputs, Level 2 [Member]          
Maturities of Long-term Debt [Abstract]          
Other Long-term Debt, Noncurrent   233      
Other Debt Facilities - Current          
Unamortized Debt Issuance Expense   0      
Maturities of Long-term Debt [Abstract]          
Debt Instrument, Unamortized Discount   0      
Current portion of long-term debt   242      
Other Debt Facilities - Current | Fair Value, Inputs, Level 2 [Member]          
Maturities of Long-term Debt [Abstract]          
Current portion of long-term debt   $ 242      
v3.25.4
Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Accounts Payable and Accrued Liabilities, Current [Abstract]    
Payroll and incentives $ 71,406 $ 74,984
Employee benefits 48,128 44,183
Deferred revenue 160,194 140,212
Federal, non-U.S. and state income taxes 80,565 74,403
Operating Lease liabilities, Accrued, Current 30,035 23,582
Other accrued operating expenses 166,626 128,031
Accrued expenses and other current liabilities $ 556,954 $ 485,395
v3.25.4
Employee Benefit Plans (Schedule of Net Benefit Costs, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 3,253 $ 5,017 $ 5,736
Interest cost 9,398 17,008 19,585
Expected return on plan assets (4,003) (12,899) (14,600)
Actuarial loss (gain) (5,188) 1,188 9,341
Net periodic benefit cost $ 3,460 $ 10,314 $ 20,062
v3.25.4
Employee Benefit Plans (Schedule of Net Funded Status, Pension Plans) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Actuarial assumptions as of the year-end measurement date:        
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Projected Benefit Obligation $ 132,279 $ 126,172    
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets 0 0    
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation 132,279 126,172    
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets 0 $ 0    
Defined Benefit Plan, Plan Assets, Excess Plan Assets Reverted After Sale 2,700      
Other Pension Plan [Member]        
Actuarial assumptions as of the year-end measurement date:        
Defined Benefit Plan, Actuarial Assumptions Used to Remeasure Pension Obligation and Plan Assets at Year-end, Rate of Compensation Increase   3.19%    
Other Postretirement Benefit Plans, Defined Benefit [Member]        
Net amounts recognized in the consolidated balance sheets consist of:        
Net amounts recognized in the consolidated balance sheets 21,200 $ 19,200    
Foreign Plan [Member]        
Actuarial present value of benefit obligations: [Abstract]        
Accumulated benefit obligations 132,279 212,120    
Change in benefit obligations:        
Projected benefit obligations at beginning of year 212,120 227,579    
Service cost 1,811 3,442    
Defined Benefit Plan, Change in Benefit Obligations, Interest Cost 4,476 7,966    
Actuarial loss (gain) (4,065) (2,950)    
Effect of exchange rate changes 15,333 (9,147)    
Projected benefit obligations at end of year 132,279 212,120 $ 227,579  
Change in plan assets:        
Fair value of plan assets at beginning of year 93,500 112,305    
Actual return on plan assets 0 (9,513)    
Benefits paid and plan expenses (8,045) (14,770)    
Employer's contributions 8,045 7,066    
Defined Benefit Plan, Plan Assets, Payment for Settlement (89,351) 0    
Defined Benefit Plan, Plan Assets, Returned To Employer (3,271) 0    
Participant's contributions 0 0    
Effect of exchange rate changes (878) (1,588)    
Fair value of plan assets at end of year 0 93,500 $ 112,305  
Net amounts recognized in the consolidated balance sheets consist of:        
Assets for Plan Benefits, Defined Benefit Plan 0 7,552    
Current liabilities (7,962) (7,099)    
Noncurrent liabilities (124,317) (119,073)    
Net amounts recognized in the consolidated balance sheets $ (132,279) $ (118,620)    
Actuarial assumptions as of the year-end measurement date:        
Defined Benefit Plan, Actuarial Assumptions Used to Remeasure Pension Obligation and Plan Assets at Year-end, Discount Rate 3.90% 4.19%    
Defined Benefit Plan, Actuarial Assumptions Used to Remeasure Pension Obligation and Plan Assets at Year-end, Rate of Compensation Increase 3.18%      
Defined Benefit Plan, Benefit Obligation, Benefits Paid $ 8,045 $ 14,770    
Defined Benefit Plan, Benefit Obligation, Payment for Settlement (89,351) 0    
Defined Benefit Plan, Plan Assets, Payment for Settlement $ 89,351 $ 0    
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 4.19% 3.69% 4.12%  
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase 3.19% 3.19% 3.16%  
Expected rate of return on assets   0.00% 3.78% 3.92%
UNITED STATES        
Actuarial present value of benefit obligations: [Abstract]        
Accumulated benefit obligations $ 91,185 $ 90,293    
Change in benefit obligations:        
Projected benefit obligations at beginning of year 90,293 208,505    
Service cost 1,425 1,575    
Defined Benefit Plan, Change in Benefit Obligations, Interest Cost 4,922 9,042    
Actuarial loss (gain) 3,262 (11,573)    
Effect of exchange rate changes 0 0    
Projected benefit obligations at end of year 91,185 90,293 $ 208,505  
Change in plan assets:        
Fair value of plan assets at beginning of year 91,777 202,331    
Actual return on plan assets 7,965 6,702    
Benefits paid and plan expenses (9,571) (20,986)    
Employer's contributions 0 0    
Defined Benefit Plan, Plan Assets, Payment for Settlement 0 (96,270)    
Defined Benefit Plan, Plan Assets, Returned To Employer 0 0    
Participant's contributions 2,147 0    
Effect of exchange rate changes 0 0    
Fair value of plan assets at end of year 92,318 91,777 $ 202,331  
Net amounts recognized in the consolidated balance sheets consist of:        
Assets for Plan Benefits, Defined Benefit Plan 1,133 1,484    
Current liabilities 0 0    
Noncurrent liabilities 0 0    
Net amounts recognized in the consolidated balance sheets $ 1,133 $ 1,484    
Actuarial assumptions as of the year-end measurement date:        
Defined Benefit Plan, Actuarial Assumptions Used to Remeasure Pension Obligation and Plan Assets at Year-end, Discount Rate 5.29% 5.71%    
Defined Benefit Plan, Actuarial Assumptions Used to Remeasure Pension Obligation and Plan Assets at Year-end, Rate of Compensation Increase 0.00% 0.00%    
Defined Benefit Plan, Benefit Obligation, Benefits Paid $ 8,717 $ 20,986    
Defined Benefit Plan, Plan Assets, Payment for Settlement, Net of Refunds (94,100)      
Defined Benefit Plan, Benefit Obligation, Payment for Settlement 0 (96,270)    
Defined Benefit Plan, Plan Assets, Payment for Settlement $ 0 $ 96,270    
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 5.71% 4.54% 4.84%  
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase 0.00% 0.00% 0.00%  
Expected rate of return on assets   4.60% 4.60% 4.80%
v3.25.4
Employee Benefit Plans (Schedule of Allocation of Plan Assets, Pension Plans) (Details)
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities   100.00%
UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 100.00%  
Defined Benefit Plan, Equity Securities 100.00% 100.00%
Minimum [Member] | Equity Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 0.00%  
Minimum [Member] | Equity Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 0.00%  
Minimum [Member] | Debt Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 0.00%  
Minimum [Member] | Debt Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 90.00%  
Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 95.00%  
Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 0.00%  
Maximum [Member] | Equity Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 5.00%  
Maximum [Member] | Equity Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 10.00%  
Maximum [Member] | Debt Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 5.00%  
Maximum [Member] | Debt Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 100.00%  
Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 100.00%  
Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit, Target Asset Allocation Percentage, Next Fiscal Year 10.00%  
Other Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities   100.00%
Other Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities 0.00% 0.00%
Debt Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities   0.00%
Debt Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities 95.00% 95.00%
Equity Securities [Member] | Foreign Plan [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities   0.00%
Equity Securities [Member] | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Defined Benefit Plan, Equity Securities 5.00% 5.00%
v3.25.4
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 92,318 $ 185,277  
Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 615 7,555  
Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,833 3,049  
Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,149 887  
Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 484 403  
Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 87,237 83,267  
Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   1,630  
Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   88,486  
Fair Value, Inputs, Level 1 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 5,081 37,799  
Fair Value, Inputs, Level 1 [Member] | Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 615 7,555  
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,833 3,049  
Fair Value, Inputs, Level 1 [Member] | Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,149 887  
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 484 403  
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 25,905  
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Fair Value, Inputs, Level 1 [Member] | Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Fair Value, Inputs, Level 2 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 87,237 58,992  
Fair Value, Inputs, Level 2 [Member] | Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 87,237 57,362  
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   1,630  
Fair Value, Inputs, Level 2 [Member] | Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Fair Value, Inputs, Level 3 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 88,486  
Fair Value, Inputs, Level 3 [Member] | Cash [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Large-cap [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Equity Securities, International large-cap value[Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Bonds [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Fair Value, Inputs, Level 3 [Member] | Foreign liability driven investment [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 0 $ 88,486 $ 100,666
v3.25.4
Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year $ 185,277  
Fair value of plan assets at end of year 92,318 $ 185,277
Foreign liability driven investment [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year 88,486  
Fair value of plan assets at end of year   88,486
Equity Securities, Emerging Markets Growth [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year 403  
Fair value of plan assets at end of year 484 403
Fair Value, Inputs, Level 3 [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year 88,486  
Fair value of plan assets at end of year 0 88,486
Fair Value, Inputs, Level 3 [Member] | Foreign liability driven investment [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year 88,486 100,666
Defined Benefit Plan, Realized losses   (1,237)
Fair value of plan assets at end of year 0 88,486
Defined Benefit Plan, Unrealized Gains   (4,727)
Defined Benefit Plan, Realized Gains   (6,216)
Defined Benefit Plan, Foreign exchange losses (831)  
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Settlement of Plan Obligation (87,655)  
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member]    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets at beginning of year 0  
Fair value of plan assets at end of year $ 0 $ 0
v3.25.4
Employee Benefit Plans (Schedule of Expected Benefit Payments, Pension Plans) (Details)
$ in Thousands
Dec. 28, 2025
USD ($)
Foreign Plan [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Expected contributions in next fiscal year $ 7,900
2018 7,962
2019 7,980
2020 8,053
2021 7,819
2022 8,046
2023-2026 39,113
UNITED STATES  
Defined Benefit Plan Disclosure [Line Items]  
2018 8,458
2019 8,409
2020 8,345
2021 8,202
2022 8,027
2023-2026 $ 35,989
v3.25.4
Employee Benefit Plans (Schedule of Net Benefit Costs, Other Postretirement Benefits) (Details) - Pension Plans, Defined Benefit - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 3,253 $ 5,017 $ 5,736
Interest cost 9,398 17,008 19,585
Expected return on plan assets (4,003) (12,899) (14,600)
Actuarial loss (gain) 5,188 (1,188) (9,341)
Net periodic benefit cost $ 3,460 $ 10,314 $ 20,062
v3.25.4
Employee Benefit Plans (Schedule of Net Funded Status, Other Postretirement Benefit Plans) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Other Postretirement Benefit Plans, Defined Benefit [Member]      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Net amounts recognized in the consolidated balance sheets $ 21,200 $ 19,200  
Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 4.19% 3.69% 4.12%
Change in benefit obligations:      
Projected benefit obligations at beginning of year $ 212,120 $ 227,579  
Service cost 1,811 3,442  
Defined Benefit Plan, Benefit Obligation, Benefits Paid 8,045 14,770  
Actuarial loss (gain) (4,065) (2,950)  
Projected benefit obligations at end of year 132,279 212,120 $ 227,579
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 93,500 112,305  
Actual return on plan assets 0 (9,513)  
Defined Benefit Plan, Plan Assets, Payment for Settlement (89,351) 0  
Defined Benefit Plan, Plan Assets, Benefits Paid 8,045 14,770  
Fair value of plan assets at end of year 0 93,500 $ 112,305
Net amounts recognized in the consolidated balance sheets (132,279) (118,620)  
Assets for Plan Benefits, Defined Benefit Plan $ 0 $ 7,552  
UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 5.71% 4.54% 4.84%
Change in benefit obligations:      
Projected benefit obligations at beginning of year $ 90,293 $ 208,505  
Service cost 1,425 1,575  
Defined Benefit Plan, Benefit Obligation, Benefits Paid 8,717 20,986  
Actuarial loss (gain) 3,262 (11,573)  
Projected benefit obligations at end of year 91,185 90,293 $ 208,505
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets at beginning of year 91,777 202,331  
Actual return on plan assets 7,965 6,702  
Defined Benefit Plan, Plan Assets, Payment for Settlement 0 (96,270)  
Defined Benefit Plan, Plan Assets, Benefits Paid 9,571 20,986  
Fair value of plan assets at end of year 92,318 91,777 $ 202,331
Net amounts recognized in the consolidated balance sheets 1,133 1,484  
Assets for Plan Benefits, Defined Benefit Plan $ 1,133 $ 1,484  
v3.25.4
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Other Postretirement Benefit Plans) (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 92,318 $ 185,277  
Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 5,081 37,799  
Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 87,237 58,992  
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 88,486  
Cash [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 615 7,555  
Cash [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 615 7,555  
Cash [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Cash [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, U.S. Large-cap [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,833 3,049  
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,833 3,049  
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, International large-cap value[Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,149 887  
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,149 887  
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fixed Income Funds, Corporate Debt Instruments [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 87,237 83,267  
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 25,905  
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 87,237 57,362  
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Fixed Income Funds, Corporate Bonds [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   1,630  
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   1,630  
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Foreign liability driven investment [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   88,486  
Foreign liability driven investment [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Foreign liability driven investment [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0  
Foreign liability driven investment [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 88,486 $ 100,666
Equity Securities, Emerging Markets Growth [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 484 403  
Equity Securities, Emerging Markets Growth [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 484 403  
Equity Securities, Emerging Markets Growth [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Equity Securities, Emerging Markets Growth [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
Foreign Plan [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 93,500 112,305
UNITED STATES      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 92,318 $ 91,777 $ 202,331
v3.25.4
Employee Benefit Plans (Schedule of Expected Benefit Payments, Other Postretirement Benefits) (Details)
$ in Thousands
Dec. 28, 2025
USD ($)
Foreign Plan [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year $ 7,900
2018 7,962
2019 7,980
2020 8,053
2021 7,819
2022 8,046
2023-2026 39,113
UNITED STATES  
Defined Benefit Plan Disclosure [Line Items]  
2018 8,458
2019 8,409
2020 8,345
2021 8,202
2022 8,027
2023-2026 $ 35,989
v3.25.4
Employee Benefit Plans (Savings Plan) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation 100.00%    
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match 5.00%    
Defined Contribution Plan, 401(k) Savings Plan Expense $ 13.8 $ 13.3 $ 15.0
v3.25.4
Employee Benefit Plans (Supplemental Executive Retirement Plan) (Details) - Supplemental Employee Retirement Plans, Defined Benefit [Member] - USD ($)
$ in Millions
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]      
Projected benefit obligation $ 16.4 $ 16.4  
Fair value of plan assets 0.1 0.6  
Pension expense (income) $ 1.8 $ (0.3) $ 1.5
v3.25.4
Contingencies (Details)
$ in Millions
 12 Months Ended
Dec. 28, 2025
USD ($)
years
Dec. 29, 2024
USD ($)
Commitments and Contingencies Disclosure [Abstract]    
Number of years over which estimated environmental cost will be paid | years 10  
Accrual For Management's estimate of cost of remediation of known environmental matters | $ $ 10.8 $ 14.2
v3.25.4
Stock Plans (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total income tax benefit recognized for stock-based compensation $ 5,300 $ 8,000 $ 10,600
Aggregate intrinsic value for stock options exercisable $ 1,000    
Weighted average remaining contractual term of options exercisable (in years) 2 years 7 months 6 days    
Number of shares vested and expected to vest in the future 1,500,000    
Aggregate intrinsic value of vested and expected to vest stock options $ 2,200    
Weighted average remaining contractual term for options vested and expected to vest 4 years    
Total pre-tax stock-based compensation expense $ 22,847 37,809 41,410
Restricted Stock Awards [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted-average grant-date fair value of stock granted (per share) $ 109.71    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 21,000    
Fair value of restricted stock awards vested $ 16,000 30,900 31,500
Total pre-tax stock-based compensation expense 16,400 $ 22,300 $ 28,300
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted $ 20,300    
Shares/units granted 197,000    
Awards/units outstanding 329,000 275,000  
Weighted-average period for recognition of unrecognized compensation cost, years 1 year 9 months 18 days    
Option vesting period (in years) 3 years    
Employee Stock Purchase Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares authorized under plan 5,000,000.0    
Weighted-average grant-date fair value of stock granted (per share) $ 98.14 $ 99.62 $ 108.37
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date 95.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate 10.00%    
Shares/units granted 27,111 14,339 28,899
Shares available for grant under employee stock purchase plan 600,000    
Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted-average grant-date fair value of options $ 37.10 $ 37.85 $ 45.18
Total intrinsic value of options exercised $ 1,400 $ 4,900 $ 2,400
Cash received from option exercises 2,900 7,700 4,300
Total pre-tax stock-based compensation expense 9,200 $ 9,800 $ 9,100
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted $ 15,400    
Weighted-average period for recognition of unrecognized compensation cost, years 2 years    
Option vesting period (in years) 3 years    
Stock Options Expiration Period After Date of Grant 7 years    
2019 Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares authorized under plan     6,250,000
v3.25.4
Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 22,847 $ 37,809 $ 41,410
Cost of sales [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 2,149 2,495 4,224
Research and development expenses [Member ]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 1,577 3,863 5,276
Selling, general and administrative and other expenses [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 19,121 $ 31,451 $ 31,910
v3.25.4
Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]      
Risk-free interest rate 4.00% 4.10% 4.10%
Expected dividend yield 0.30% 0.30% 0.20%
Expected lives, years 5 years 5 years 5 years
Expected stock volatility 33.20% 33.60% 32.70%
v3.25.4
Stock Plans (Summary of Stock Option Activity) (Details)
shares in Thousands
 12 Months Ended
Dec. 28, 2025
$ / shares
shares
Stock option activity  
Shares outstanding at beginning of the year 1,160
Shares granted 371
Shares exercised (37)
Shares canceled (16)
Shares forfeited (16)
Shares outstanding at end of year 1,462
Shares exercisable at end of year 855
Number of shares vested and expected to vest in the future 1,500
Weighted-average price, outstanding at beginning of year (per share) | $ / shares $ 130.50
Weighted-average price, granted (per share) | $ / shares 105.16
Weighted-average price, exercised (per share) | $ / shares 82.16
Weighted-average price, canceled (per share) | $ / shares 142.15
Weighted-average price, forfeited (per share) | $ / shares 116.30
Weighted-average price, outstanding at end of year (per share) | $ / shares 125.32
Weighted-average price, exercisable at end of year (per share) | $ / shares $ 138.29
v3.25.4
Stock Plans (Summary of Restricted Stock Award Activity) (Details) - Restricted Stock Awards [Member]
shares in Thousands
 12 Months Ended
Dec. 28, 2025
$ / shares
shares
Restricted stock award activity  
Nonvested at beginning of year | shares 275
Shares, granted | shares 197
Shares, vested | shares (122)
Shares, forfeited | shares (21)
Nonvested at end of year | shares 329
Weighted-average grant-date fair value, nonvested at beginning of year (per share) | $ / shares $ 122.80
Weighted-average grant-date fair value of stock granted (per share) | $ / shares 109.71
Weighted-average grant-date fair value, vested (per share) | $ / shares 131.16
Weighted-average grant-date fair value, forfeited (per share) | $ / shares 112.40
Weighted-average grant-date fair value, nonvested at end of year (per share) | $ / shares $ 112.56
v3.25.4
Stockholders' Equity (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 06, 2026
Apr. 05, 2026
Dec. 28, 2025
Sep. 28, 2025
Jun. 29, 2025
Mar. 30, 2025
Dec. 29, 2024
Sep. 29, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Oct. 01, 2023
Jul. 02, 2023
Apr. 02, 2023
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
May 08, 2026
Oct. 24, 2024
Schedule of Stockholders' Equity [Line Items]                                      
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans                             37,710 86,484 103,144    
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans                             $ 4,200 $ 9,800 $ 13,100    
Cash dividends (per share)     $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 $ 0.28 $ 0.28    
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations                             $ 828,056 $ 369,368 $ 392,302    
Unrealized Foreign Exchange Losses (Gains) on Intercompany Debt in AOCI                             (165,300) $ (900) $ 11,300    
Income taxes related to foreign currency translation adjustments recognized in AOCI                             59,500        
O2025Q4Dividends [Member]                                      
Schedule of Stockholders' Equity [Line Items]                                      
Dividends accrued     $ 7,800                       $ 7,800        
Dividends Payable, Date Declared     Oct. 23, 2025                                
Repurchase Program, 10/24/2024                                      
Schedule of Stockholders' Equity [Line Items]                                      
Number of common stock repurchased in open market                             7,264,299        
Share Repurchase Program, Authorized, Amount                                     $ 1,000,000
Aggregate Cost of Repurchased Common Shares Under Repurchase Program                             $ 695,400        
Repurchase Program, 10/23/2025                                      
Schedule of Stockholders' Equity [Line Items]                                      
Number of common stock repurchased in open market                             1,245,232        
Share Repurchase Program, Remaining Authorized, Amount     $ 879,500                       $ 879,500        
Share Repurchase Program, Authorized, Amount                                     $ 1,000,000
Aggregate Cost of Repurchased Common Shares Under Repurchase Program                             $ 120,500        
Subsequent Event [Member] | O2025Q4Dividends [Member]                                      
Schedule of Stockholders' Equity [Line Items]                                      
Dividends Payable, Date to be Paid, Year and Month 2026-02                                    
Subsequent Event [Member] | O2026Q1Dividends [Member]                                      
Schedule of Stockholders' Equity [Line Items]                                      
Cash dividends (per share)   $ 0.07                                  
Dividends Payable, Date Declared   Jan. 26, 2026                                  
Dividends Payable, Date to be Paid, Year and Month                                   2026-05  
Subsequent Event [Member] | Repurchase Program, 10/23/2025                                      
Schedule of Stockholders' Equity [Line Items]                                      
Number of common stock repurchased in open market 608,907                                    
Aggregate Cost of Repurchased Common Shares Under Repurchase Program $ 64,200                                    
v3.25.4
Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Cumulative Translation Adjustment Summary [Roll Forward]        
Foreign currency translation adjustment, net of tax, beginning of year $ (394,938) $ (275,678) $ (446,664)  
Current year change 173,876 (119,260) 80,172  
Foreign currency translation adjustment, net of tax, end of year (221,062) (394,938) (275,678)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax     90,814  
Foreign currency translation adjustments, net of income taxes, reclassified to earnings 0 0 90,814  
Foreign currency translation adjustment, net of tax, Reclassification to Retained Earnings     90,814  
Unrecognized prior service costs, net of tax, reclassification to retained earnings     0  
Unrealized (losses) gains on securities, net of tax, reclassification to retained earnings     0  
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax 173,970 (119,413) 170,805  
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 173,970 (119,413) 79,991  
Unrecognized prior service costs, net of tax (798) (798) (798) $ (798)
Unrecognized prior service costs, net of tax, current year change 0 0 0  
Unrealized (losses) gains on securities, net of tax (275) (369) (216) (35)
Unrealized (losses) gains on securities, net of tax, current year change 94 (153) (181)  
Accumulated other comprehensive income (loss) $ (222,135) $ (396,105) $ (276,692) $ (447,497)
v3.25.4
Derivatives And Hedging Activities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Derivative [Line Items]      
Company's business conducted outside United States 60.00%    
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months $ 0    
European And Asian Currencies [Member]      
Derivative [Line Items]      
Maximum maturity period for foreign exchange contracts, in months 12 months    
Duration of foreign currency derivative contract, days 30 days    
Fair Value Hedging [Member]      
Derivative [Line Items]      
Derivative, Notional Amount $ 598,400 $ 409,800  
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Derivative [Line Items]      
Foreign Currency Contract, Asset, Fair Value Disclosure (1,832) (861)  
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Net Investment Hedging [Member]      
Derivative [Line Items]      
Notional Amount of Nonderivative Instruments 498,600    
Unrealized Gain (Loss) on Net Investment Hedge in AOCI $ (67,600) $ 31,700 $ (19,500)
v3.25.4
Fair Value Measurements (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 31, 2023
Dec. 29, 2024
Mar. 13, 2023
Jan. 01, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 17,869 $ 40,005 $ 21,753   $ 46,618
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases   15,900      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)   $ (1,000)      
Analytical, Food and Enterprise Services businesses          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Disposal Group, Consideration, Contingent on Exit Valuation       $ 150,000  
Senior Unsecured Notes          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Unsecured senior notes, fair value 2,963,700   2,765,500    
Sirion and Qognit [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount $ 75,300        
Business Combination, Contingent Consideration Arrangements, Maximum Period 5 years 10 months 24 days        
Business Combination, Contingent Consideration Arrangements, Weighted Average Period 3 years 8 months 12 days        
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 0   0    
Fair Value, Inputs, Level 2 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term Debt 2,631,236   3,150,476    
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0   0    
Fair Value, Inputs, Level 2 [Member] | Senior Unsecured Notes          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term Debt $ 3,222,900   3,151,500    
Fair Value, Inputs, Level 2 [Member] | Other Debt Facilities, including the senior revolving credit facility          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Other Long-term Debt     $ 500    
v3.25.4
Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Jan. 01, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 17,869 $ 21,753 $ 40,005 $ 46,618
Fair Value, Recurring [Member] | Carrying Value [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities (27,956) (27,413)    
Foreign Currency Contract, Asset, Fair Value Disclosure 1,832 861    
Foreign exchange derivative liabilities, net (1,487) (1,048)    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 17,869 21,753    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 14,890 14,890    
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities (27,956) (27,413)    
Foreign Currency Contract, Asset, Fair Value Disclosure 0 0    
Foreign exchange derivative liabilities, net 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 0 0    
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities 0 0    
Foreign Currency Contract, Asset, Fair Value Disclosure 1,832 861    
Foreign exchange derivative liabilities, net (1,487) (1,048)    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 0 0    
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities 0 0    
Foreign Currency Contract, Asset, Fair Value Disclosure 0 0    
Foreign exchange derivative liabilities, net 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 17,869 21,753    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $ 14,890 $ 14,890    
v3.25.4
Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Balance beginning of period $ (21,753) $ (40,005) $ (46,618)
Payments (2,484) (16,383) (9,741)
Change in fair value (included within selling, general and administrative expenses) 1,400 1,869 (3,128)
Balance end of period $ (17,869) $ (21,753) (40,005)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases     15,900
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)     $ (1,000)
v3.25.4
Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Leases [Abstract]      
Operating Lease, Cost $ 47,862 $ 40,957 $ 47,738
Schedule Of Supplemental Cash Flow Information Related To Leases [Line Items]      
Operating Lease, Payments 37,179 33,198 42,597
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability $ 17,249 $ 47,649 $ 10,049
v3.25.4
Leases Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]    
Operating Lease, Right-of-Use Asset $ 165,439 $ 167,716
Operating Lease, Liability 178,143 175,087
Operating Lease, Liability, Noncurrent $ 148,108 $ 151,505
Operating Lease, Weighted Average Remaining Lease Term 7 years 3 months 18 days 8 years 2 months 12 days
Operating Lease, Weighted Average Discount Rate, Percent 4.90% 4.70%
Operating lease liabilities included in Accrued expenses and other current liabilities $ 30,035 $ 23,582
v3.25.4
Leases Lessee, Operating Lease, Liability, Maturity (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Operating Lease Liabilities, Maturity [Line Items]      
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months $ 37,328    
Lessee, Operating Lease, Liability, Payments, Due Year Two 35,369    
Lessee, Operating Lease, Liability, Payments, Due Year Three 29,214    
Lessee, Operating Lease, Liability, Payments, Due Year Four 23,760    
Lessee, Operating Lease, Liability, Payments, Due Year Five 20,094    
Lessee, Operating Lease, Liability, Payments, Due after Year Five 66,155    
Operating Lease, Payments 37,179 $ 33,198 $ 42,597
Lessee, Operating Lease, Liability, Payments, Due 211,920    
Lessee, Operating Lease, Liability, Undiscounted Excess Amount (33,777)    
Operating Lease, Liability $ 178,143 $ 175,087  
v3.25.4
Schedule of Sales and Operating Income from Continuing Operations by Operating Segment (Details)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
USD ($)
segments
Dec. 29, 2024
USD ($)
Dec. 31, 2023
USD ($)
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue $ 2,856,051 $ 2,755,026 $ 2,750,571
Interest and other expense (income), net (88,358) (30,615) (117,586)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 268,277 316,126 182,976
Asset Impairment Charges 4,784 22,814 0
Amortization of Intangible Assets $ 335,600 359,400 365,100
Number of Reportable Segments | segments 2    
Reportable Segment Revenue [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue $ 2,856,051 2,755,026 2,750,571
Segment Operating Income [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment operating income 802,428 821,214 810,277
Reconciling Item (to Reconcile Segment Operating Income to Income from Continuing Operations before Income Taxes) [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Corporate Expenses (28,944) (41,754) (40,417)
Significant litigation matters and settlements (12,228) (7,775)  
Asset Impairment Charges 0 (22,814) 0
Significant environmental matters 1,208 0 (2,457)
Amortization of Intangible Assets (335,586) (359,376) (365,113)
Purchase accounting adjustments (1,248) 79 (5,956)
Acquisition and divestiture-related costs (3,783) (25,379) (69,159)
Restructuring and Other, net (55,932) (17,454) (26,601)
Significant litigation matters and settlements, Income     (12)
Transformation costs (9,280) 0 0
Diagnostics [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue 1,424,947 1,356,425 1,292,379
Segment operating income 344,166 353,938 298,027
Diagnostics [Member] | Reportable Segment Revenue [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue 1,424,947 1,356,425 1,292,379
Diagnostics [Member] | Segment Operating Income [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment Cost of Revenue 633,769 576,162 548,612
Segment Selling, general and administrative expenses 343,430 336,325 341,155
Segment research and development expenses 103,582 90,000 104,585
Life Sciences [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue 1,431,104 1,398,601 1,458,192
Segment operating income 458,262 467,276 512,250
Life Sciences [Member] | Reportable Segment Revenue [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment revenue 1,431,104 1,398,601 1,458,192
Life Sciences [Member] | Segment Operating Income [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Segment Cost of Revenue 516,297 488,188 510,445
Segment Selling, general and administrative expenses 344,516 338,755 328,068
Segment research and development expenses $ 112,029 $ 104,382 $ 107,429
v3.25.4
Industry Segment and Geographic Area Information Schedule of Depreciation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation expense $ 69,755 $ 68,473 $ 66,655
Life Sciences [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation expense 33,485 30,128 30,110
Diagnostics [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation expense 33,403 36,074 33,994
Corporate (Reconciling Item) [Member]      
Schedule of Segment Reporting Information, by Segment [Line Items]      
Depreciation expense $ 2,867 $ 2,271 $ 2,551
v3.25.4
Industry Segment and Geographic Area Information Schedule of Total Assets by Segment (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Schedule of Total Assets, by segment [Line Items]    
Assets $ 12,168,411 $ 12,392,478
v3.25.4
Industry Segment and Geographic Area Information Schedule of Revenue by Geographic Area (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Sales by Geographic Area [Line Items]      
Segment revenue $ 2,856,051 $ 2,755,026 $ 2,750,571
UNITED STATES      
Sales by Geographic Area [Line Items]      
Segment revenue 1,126,274 1,097,856 1,117,654
CHINA      
Sales by Geographic Area [Line Items]      
Segment revenue 425,060 450,007 454,426
UNITED KINGDOM      
Sales by Geographic Area [Line Items]      
Segment revenue 126,849 112,883 125,419
GERMANY      
Sales by Geographic Area [Line Items]      
Segment revenue 177,664 162,575 193,170
Other International [Member]      
Sales by Geographic Area [Line Items]      
Segment revenue 1,000,204 931,705 859,902
Total international [Member]      
Sales by Geographic Area [Line Items]      
Segment revenue $ 1,729,777 $ 1,657,170 $ 1,632,917
v3.25.4
Industry Segment and Geographic Area Information Schedule of Long-Lived Assets by Geographic Location (Details) - USD ($)
$ in Thousands
Dec. 28, 2025
Dec. 29, 2024
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets $ 749,031 $ 745,880
UNITED STATES    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 341,172 348,868
GERMANY    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 130,645 134,713
CHINA    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 34,894 49,207
UNITED KINGDOM    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 40,839 35,097
Other International [Member]    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets 201,481 177,995
Total international [Member]    
Long-lived assets by Geographic Area [Line Items]    
Total net long-lived assets $ 407,859 $ 397,012
v3.25.4
Subsequent Events (Details) - United States of America, Dollars - Advanced Chemistry Development Inc. [Member] - Subsequent Event [Member]
$ in Millions
 3 Months Ended
Apr. 05, 2026
USD ($)
Subsequent Event [Line Items]  
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments $ 72.0
Business Combination, Contingent Consideration, Liability $ 8.0